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Abstract
Tuberculosis is the leading cause of death due to a single infectious agent and is
spread from person to person by coughed aerosols. Individuals with tuberculosis lung
cavities spread disease more frequently than individuals without cavities. Unfortu-
nately, few studies address the mechanistic drivers of tuberculosis. The first chapter
of this manuscript describes the prevalence of cavitary tuberculosis among cases of
active tuberculosis based on a retrospective study of 3000 autopsies. Our results show
that the frequency of cavitation among cases of active tuberculosis is 15% and this
statistic may inform computational models of disease transmission. One obstacle to
studying the mechanism of tuberculosis cavitation is the difficulty in modeling tu-
berculosis cavities. Chapter 2 of this manuscript describes and characterizes a novel
rabbit model of cavitary tuberculosis based on repetitive aerosol infection. We found
that repetitive aerosol infection exacerbates disease and increases the frequency of
cavitation from 25% for a single infection to 60-80% during repetitive infections even
when the total exposure is the same between groups. These results suggest that
repetitive exposure may drive worse disease and cavitation in high-incidence settings.
Chapters 3 and 4 investigate the biochemical drivers of cavitation in tuberculosis.
Previous studies suggest that extracellular matrix breakdown enables cavitation, but
the identity of the host-expressed protein mediators of matrix breakdown remain un-
resolved. We applied the repetitive aerosol model described in Chapter 2 to study
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small-molecule mediated inhibition of extracellular collagenases during cavity forma-
tion. Chapter 3 describes the inhibition of the collagenase MMPs by cipemastat. We
found that cipemastat monotherapy was unable to reduce the frequency or extent
of cavitary disease, suggesting that collagenase MMPs are not primary mediators
of matrix breakdown. Chapter 4 describes preliminary studies on the inhibition of
cathepsin K using odanacatib. These studies show strong support for cathepsin K as
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rabbit model. Dr. André Kübler and Dr. Brian Luna pioneered many of the tech-
niques that I now take for granted, but which enabled the studies in this dissertation.
Dr. Luna is one of the greatest teachers that I know and Dr. Kübler is equally so as
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Introduction: the pathobiology of
tuberculosis cavities
Michael E. Urbanowski · Alvaro A. Ordonez
“Out of the night that covers me,
Black as the pit from pole to pole,
I thank whatever gods may be
For my unconquerable soul.
In the fell clutch of circumstance
I have not winced nor cried aloud.
Under the bludgeonings of chance
My head is bloody, but unbowed.
Beyond this place of wrath and tears
Looms but the Horror of the shade,
And yet the menace of the years
Finds and shall find me unafraid.
It matters not how strait the gate,
How charged with punishments the scroll,
I am the master of my fate,
I am the captain of my soul.”
Invictus by William Ernst Henley (1888).
Written from his bed as he battled with
tuberculosis.
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A lung cavity is the most dangerous consequence of pulmonary tuberculo-
sis. Individuals that develop tuberculosis cavities are often sicker and more likely to
aerosolize bacilli than those without cavities1. But, in the antibiotic era, cavities are
contextualized as the extreme outcome of treatment failure and are one of the least-
studied aspects of tuberculosis. In this introduction, we review cavities as dynamic
physical and biochemical structures that interface the host-response with a unique
mycobacterial niche to drive morbidity and transmission in tuberculosis. Our goal is
to provide an insightful and thoughtful interdisciplinary review of the pathogenesis
and consequences of tuberculosis cavitation.
To accomplish our goal, we examine insights from studies in epidemiology,
pathology, pathophysiology, biochemistry and microbial ecology. Wherever possible,
we draw parallels between these studies to build a more comprehensive conceptual
model for the role of cavities in tuberculosis. Finally, we also highlight remaining enig-
mas surrounding tuberculosis cavities with the aim of helping researchers to design
future studies.
The architecture of tuberculosis cavities
A lung cavity is a pathologic gas-filled space in the lung with a border, or wall,
which has a density close to water2. A tuberculosis cavity is a cavitary focus caused
by infection with a pathogen of the Mycobacterium tuberculosis (M. tb) complex.
Among tuberculosis cavities there is considerable heterogeneity in size, morphology
and wall-composition.
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Examples of tuberculosis cavities at autopsy
Figure I.1: Examples of tuberculosis lung pathology and cavities at autopsy. (A) The miliary
pattern of tuberculosis in the lung. No cavities are present. (B) An example of a massive caseous
tubercle in the lung. (C-K) Examples of tuberculosis cavities. Red arrows indicate cavities. (C-
D) Two examples of cavities with nodular type morphology. The bright white regions in C are
caseum. (E-H) Examples of intermediate size cavities, often within the apical lobe of the lung. (I-K)
Examples of large apical cavities showing abscess-like morphology. In I the entire apical lobe has
eroded. All images were obtained from the Johns Hopkins University Chesney Medical Archives and
correspond to autopsy cases between 1920 and 1950. All images were collected from the Archives
under IRB approval and used with permission.
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Radiologic patterns of tuberculosis cavities
Radiologically, cavities are described by their size, shape, and wall thickness. Size is
often correlated with the extent of disease3. Estimates for the average cavity size in
adults with tuberculosis vary between 3 and 10 cm4. Small cavities can have diam-
eters as small as 0.5 mm and demonstrate nodular morphology while large cavities
fill entire lung lobes. The morphology of large cavities is often more complicated,
consisting of multiple connected semi-cavernous air spaces embedded in a large area
of consolidation and often in-association with smaller cavities eroded from the same
dense abscess-like area5. It is likely that large cavities arise from the joining of multi-
ple smaller cavitary foci within the same disease focus. Likewise, wall-thickness and
shape may have diagnostic and prognostic value6–8. Thin-walled cavities often have
well-defined inner and outer boundaries and small thin-walled cavities appear to arise
from discrete nodules. Thick-walled cavities demonstrate a high potential for cavity
growth and dynamic behavior, so eroding thick-walled cavities may be the precursors
of larger thin-walled cavities as more caseum sloughs from the cavity wall.
Most large cavities occur in the lung apices while small nodular cavitites can
occur throughout the lungs2. Importantly, the spatial pattern of pulmonary cavi-
tation is similar to the spatial pattern of lung consolidation in tuberculosis. The
mechanistic drivers of apically-oriented disease are still debated, but most studies
agree that antigen-experienced immunocompetent individuals with active disease are
at the greatest risk for extensive apical lung disease and cavitation9. At least two
factors contribute to this pattern. First, an intact immune system likely drives ex-
tensive cavitation. Immunocompromised individuals, such as those with AIDS, are
less likely to have lung cavities, but when cavitation does occur, the cavities are dis-
tributed throughout the lungs and more likely to have a small nodular appearance.
Second, virulence factors associating with the mycobacterial pathogen also contribute
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to cavitation. Individuals with pulmonary non-tuberculosis mycobacterial infections
are also less likely to undergo extensive cavitation at the lung-apices and more likely
to have distributed small nodular cavities7.
The histologic architecture of tuberculosis cavities
The prototypical tuberculosis cavity wall contains three histologic regions.
1. GPA: At the boundary between normal-appearing lung tissue and the cavity-
wall begins a region of granulocytic pneumonia where the underlying alveoli and
lung-tissue remains intact (GPA), though filled with inflammatory cells. These
inflammatory cells consist of activated macrophages, clusters of lymphocytes,
and sporadic neutrophils among the resident pneumocytes, bronchial epithelial
cells, and vascular endothelial cells already present in the lung.
2. GPE: Moving towards the interior surface of the cavity-wall, is a region of
granulocytic pneumonia where the alveolar structure is effaced (GPE). This
region also contains activated macrophages and occasional neutrophils. Lym-
phocytes are clustered sporadically, but fibroblasts are present and participate
in pathologic collagen remodeling. This remodeling is visible with appropriate
histologic stains as a fibrotic rim of varying density and thickness. Greater
amounts of fibrosis are associated with older lesions. The GPE contains spo-
radic multinucleated giant cells. The density of multinucleated giant cells is
variable between lesions. Finally, the GPE also contain regions of lipid-laden
foamy macrophages. In some lesions, foamy macrophages concentrate along the
inner boundary of the GPE in a region of cell death. At this inner boundary,
cells can be found with necrotic cell fragments. Intracellular acid-fast mycobac-
5
Example CT scan reconstructions of tuberculosis cavities
Figure I.2: Examples CT scan reconstructions of tuberculosis cavities. (A-C) All reconstructions
are rendered in the transverse plane. Red-arrows indicate the cavity wall. (A) An example of a
cavity showing nodular type morphology. (B) An example of an intermediate size cavity with thick
walls. (C) An example a large abscess like apical cavity of the lung. All images were obtained from
the NIAID TB Portals Program Website licensed as part of the Public Domain10.
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terial bacilli are found sporadically throughout the GPE and their concentration
is variable between intra-lesion regions and between different lesions.
3. NL: Along the interior surface of the cavity-wall is a layer of necrotic cellular
debris (NL). The border between the GPE and the NL is abrupt and marked by
extensive cell necrosis. Extracellular fibrotic filaments are also rapidly depleted
at the border between the GPE and the NL leaving the NL devoid of extra-
cellular matrix. The NL typically contains high concentrations of extracellular
mycobacteria.
The clinical importance and epidemiology of tuberculosis cav-
ities
Lung cavitation is a pathologic hallmark of post-primary tuberculosis, but it is hard
to report the prevalence of cavitation among individuals with active tuberculosis
since the actual prevalence depends heavily on the identity of the survey population.
Some estimates show discordance between 10% and 50%4,11. Factors such as im-
mune status12, severity of disease, age, and screening modality all influence the risk
of cavitation. In chapter 1 of this manuscript, we describe a study of 3000 tubercu-
losis autopsy records from the years between 1920 and 1950. Our study shows that
the prevalence of cavitation among cases of active tuberculosis (where tuberculosis
was clinically assessed as the cause of death) was 15%. Therefore, the fraction of
individuals with cavities over all cases of active tuberculosis is relatively small.
Not all individuals with active tuberculosis show the same potential to transmit
tuberculosis. In their historic experiment using guinea-pigs to “catch” transmission
events from a specially ventilated tuberculosis ward, Riley et al., noted that two of 62
patients involved in their study were responsible for the vast-majority of transmission
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events13. These results suggest the existence of tuberculosis super-spreaders even
among cases of active tuberculosis. Cavitation is a likely cause of the super-spreader
phenotype, a hypothesis that is physically plausible since cavities allow the pulmonary
airways to be continuous with high concentrations of bacteria along the inner edge of
a cavity14. Moreover, tuberculosis cavities are associated with higher bacillary load
in sputum1 and the degree of sputum bacillary load is correlated with transmission15.
Finally, Bailey et al. interviewed 292 cases of newly diagnosed tuberculosis and
compared the interview results to the frequency of tuberculin-skin-test conversion
among close contacts of the 292 cases16. The research team identified tuberculosis
cavitation as the strongest factor associating with high rates of tuberculin-skin-test
conversion among contacts. Therefore, it is likely that cavitation is the major driver
of tuberculosis transmission.
In addition to driving transmission, several additional characteristics of cavi-
ties have clinical importance and make cavitary tuberculosis harder to treat.
1. High concentrations of extracellular bacteria grow in the loose necrotic
debris at the interior surface of the cavity14,17. In histologic studies, mi-
croscopic identification of acid-fast bacilli is insensitive due to the scarcity of
bacilli in tubercles of granulomatous pneumonia. However, the necrotic debris
along the inner walls of tuberculosis cavities often show a high concentration of
bacilli. These bacilli are poised to slough off of the cavity wall and coughed out
of the lungs.
2. Genetic variability and drug resistance arise from the bacterial pop-
ulation bloom within the cavity. Kaplan et al. investigated the genetic
diversity of M. tb bacilli isolated from the lungs of patients with tuberculosis
and found that the cavity surface was the site of the greatest bacterial prolifer-
ation and genetic diversification18. Describing Kaplan et al.’s work and others,
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Yoder et al. reviewed the rates of drug-specific resistance patterns and com-
pared these rates to the size of the bacterial population within cavitites19. The
authors highlight that the tremendous increase in population size at the interior
surface of the cavity meant that drug-specific resistance was likely to emerge
within the cavity.
3. Anti-mycobacterial drug penetration to the necrotic debris at the in-
ner surface of the cavity is greatly reduced20. The wall of the cavity
reduces penetration of chemotherapeutic drugs to the sites of high bacillary
concentration within the necrotic debris. Factors such as reduced vascularity
within the GPE
21 and the non-specific binding properties of necrotic debris22,23
contribute to suboptimal drug delivery. Finally, suboptimal drug concentra-
tions within the cavity may provide a selective pressure that enriches for drug-
resistant isolates.
4. The interior layer of necrotic debris inside the cavity is protected from
the immune system. Host cells generally do not live within the necrotic layer
of the cavity wall. Therefore, the regions of the cavity with the highest rates of
bacterial replication coincides with an immune-sheltered zone.
5. Healing processes are unable to regenerate the lung matrix destroyed
during cavitation. The extracellular matrix and basement membrane of the
lung are destroyed during the pathogenesis of cavities. The healing response to
lung matrix insult is pathologic fibrosis which does not support regrowth of the
complex three dimensional architecture of the lung. Therefore, cavities often
persist even after they are sterilized of mycobacteria or are replaced with scar
tissue. Therefore, cavitation can lead loss of lung volume and chronic pulmonary
deficits24.
6. Cavities that persist following curative therapy are at risk for sec-
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ondary colonization by opportunistic infections. If a cavity persists fol-
lowing curative therapy, the inner cavity wall remains an immune-sheltered
site. Furthermore, fibrosis within the wall effaced the alveolar and bronchiolar
architecture that normally supports innate immune defenses against inhaled op-
portunistic pathogens. The combination of high humidity, immune-sheltering,
and lack of innate-defenses provide an opportunity for secondary colonization,
often by species of Aspergillus25.
Experimental models of tuberculosis cavitation
Modeling tuberculosis cavities for experimental studies and pre-clinical studies is dif-
ficult. Cavities are the consequence of chronic granulomatous inflammation and even
among individuals with active tuberculosis, the frequency of cavitation is less than
50%. Dannenberg et al. summarized the animal models that develop cavities after
experimental infection. As of 2006, these were limited to non-human primates and
rabbits26,27. Importantly, the common mouse and guinea pig models do not, or rarely,
develop cavities. The models of cavitary tuberculosis were reviewed by Helke et al.
in 200628. However, it has now been more than 10 years since this last comprehen-
sive review and important advances in modeling cavities have been contributed by
many investigators. In this section we describe a few of the characteristics and recent
advances in modeling tuberculosis cavities.
Non-human primate models
Because of their genomic, physiological and immunological similarities with humans,
non-human primates are a very valuable model for multiple infectious diseases, includ-
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ing tuberculosis. Since the 1950s, non-human primates have been used to evaluate
tuberculosis pathogenesis and have provided significant advances in the field29–33.
Multiple M. tb strains (Erdman, H37Rv, 5159 and CDC1551) at different inoculum
doses and infection routes (intratracheal instillation or aerosol delivery) have been
evaluated in non-human primates32,33. Initial experiments performed between 1955
and 1975 included thousands of rhesus macaques and describe pathological findings,
evaluate possible vaccines, and study the response to anti-tuberculosis therapies34.
However, most research published during these decades did not describe cavitary le-
sions specifically, instead reporting them combined with other necrotic lesions29,35–37.
More recently, cynomolgus macaques have been used as a model for tuberculosis, char-
acterized by a lower progression to active disease compared to rhesus macaques38,39.
After infection at low doses (approximately 25 CFU via bronchoscopic instillation),
cynomolgus macaques develop active disease, latent infection or subclinical disease,
thereby representing the spectrum of human M. tb infection40–42. In this model, cav-
itary lesions have been identified in approximately 15% of the infected animals41,43.
The typical histopathological findings associated with cavitation include necrotic de-
bris admixed with inflammatory cells ulcerating and expanding bronchial airways,
eventually leading to cavities42. Capuano et al. reported the infection of 17 cynomol-
gus macaques with a low dose of M. tb, with two monkeys developing cavities by week
32-34 post-infection. At necropsy, large cavitary lesions were observed in the cranial
(apical in humans) lobes with infiltration into airways41.
Another non-human primate evaluated as a tuberculosis model of cavitation
is the marmoset, which has significant advantages such as smaller size, propensity
to bear dizygotic twins, ease of husbandry, availability of immunologic reagents and
use as an accepted toxicology model44,45. Using common marmosets, Via et al. eval-
uated the lung pathology after infection with three strains of the M. tb-complex46.
At necropsy, all of the animals showed evidence of pulmonary lesions consistent with
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active tuberculosis. Half of the marmosets infected with M. tb CDC 1551 devel-
oped cavities after aerosol infection, but the animals infected with M. tb K04 (Beijing
subfamily) or M. africanum strain N0091 had primarily invasive granulomatous pneu-
monia, more extra-pulmonary disease but no cavitation. Intratracheal infection with
M. tb Erdman also resulted in extensive disease. Lung lesions in the animals in-
fected with M. tb CDC 1551 had more defined margins, with peripheral fibrosis, less
loose histiocytic infiltration, and lower bacterial loads in apparently normal lung,
suggesting partial immunological containment46. A subsequent study showed that
marmosets infected with M. tb CDC 1551 and treated with a standard four-drug com-
bination (isoniazid, rifampin, pyrazinamide, and ethambutol) resolve disease faster
compared to marmosets treated with isoniazid and streptomycin, measured by 18F-
FDG PET/CT47. While at the start of treatment (6 weeks post-infection), cavitary
lesions were only evident in the CT of 1 out of 22 animals, 6 weeks after treatment,
11 (50%) marmosets had cavitary lesions. The bacterial burden of the cavities was
significantly different between treatment groups. Based on these experiments, Ca-
dena et al. evaluated a low bacterial burden model and bronchoscopically infected
common marmosets with the more virulent M. tb Erdman strain or the less viru-
lent CDC 1551 strain at low doses (1-7 CFU), following the disease progression with
18F-FDG PET/CT48. The Erdman-infected animals had significant disease 4 weeks
post-infection, while the marmosets infected with CDC 1551 had a slower progression
with 1 of the 2 animals developing multiple cavitary lesions.
Rabbit models
Rabbits have been used as tools and models in the study of tuberculosis for over
100 years. Importantly, rabbits infected by aerosolized M. tb develop a spectrum
of lesions similar to human disease, including cavities. Therefore, the rabbit model
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is advantageous in investigations where the composition, structure, and spatial rela-
tionship between lesions are important for the hypothesis being tested. Rabbit lungs
are also much larger than guinea-pig or mouse lungs, allowing investigators to collect
and compare tissue from spatially distinct regions of infected lungs. Finally, rabbits
are significantly cheaper and more efficient to house and maintain compared to non-
human primates and the use of rabbits instead of non-human primates for mutually
appropriate applications is consistent with the Three Rs of animal welfare in research.
The use of rabbits for tuberculosis research has two major disadvantages in
contemporary studies. First, The paucity of rabbit-specific immunological reagents
has limited the study of infection and immunity in rabbits. Second, rabbits are
relatively outbred compared with murine models. Therefore, the rabbit response to
M. tb infection is heterogenous and some rabbits develop a progressive syndrome
while others successfully control the infection.
The most advanced experimental studies on the mechanism of cavitation have
been conducted in rabbits. Here we briefly review the major advancements in rabbit
models of tuberculosis cavitation during the past century.
1. A robust immune response to mycobacterial antigen increases the
likelihood of cavitation: Lurie used rabbits extensively for his work on the
pathogenesis and immune protection from M. tb infection49. The seminal mech-
anistic investigations on the cavity-inducing elements of the mycobacterial cell
wall were conducted by Yamamura in rabbits during the 1950-80s50–53. Inde-
pendently, Yamamura and Lurie both concluded that a robust immune response
was necessary for cavity formation.
2. Careful determination of the frequency of cavitation following aerosol
infection: In 1996, Converse et al. quantified cavitation in rabbits following
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aerosol challenges of varying concentration and reported that approximately
half of the rabbits had cavities following inhalation of 200-800 bacilli54.
3. The innovation of the bronchoscope-targeted instillation model: Fi-
nally, Nedeltchev et al. provided an additional innovation of the rabbit model
by generating cavities using bronchoscopic instillation of high-burden inocu-
lum55. Nedeltchev’s protocol used pre-sensitization of rabbits by intra-dermal
injections of heat-killed Mycobacterium bovis to sensitize the immune system
to mycobacterial antigen. The use of “sensitization” to drive cavitation was
based on observations by Lurie and Yamamura, and the experiences of Dannen-
berg. The bronchoscope-target model was further refined and characterized by
Kübler56.
Based on the work by Dannenberg, Converse, Nedeltchev and Kübler, current
rabbit models of cavitation fall into two groups. Each model has important but
distinct characteristics for advancing research on tuberculosis cavitation.
1. Cavitation by bronchoscope targeted instillation: This model generates
a single large necrotic focus reminiscent of abscess-like cavitation observed in
cases of extensive lung disease. Cavitation often occurs after 1-month follow-
ing inoculation, a much-shorter time-course than was reported by Wells and
Lurie57 following aerosol-delivered infection, but consistent with Yamamuras ex-
periments which used trans-thoracic injection of cell-wall components to cause
cavitation50. Therefore, this model is probably inappropriate for studies on the
natural pathogenesis of cavities due to the artificial nature of the high-dose
intra-bronchial inoculation. However, we highlight the strengths of this model
for studies in lung-destruction and drug penetration into the caseum of cavity
walls.
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2. Cavitation by aerosol exposure: Cavitation by aerosol exposure is a better
model for the natural pathogenesis of tuberculosis cavities. Rates of cavitation
are historically variable between rabbits and between investigators. In our expe-
rience, 15-25% of rabbits receiving a day-1 implantation of approximately 2,500
CFU of M. tb (H37Rv) cavitate by week-10 following exposure. These rates are
similar to the rates observed in humans with active tuberculosis. The typical
cavity morphology is also different from cavities generated by bronchoscope tar-
geted instillation and resembles tuberculosis cavities with nodular morphology.
In Chapter 2 of this manuscript we report a novel variation on the aerosol
exposure model based on repeated aerosol exposure. In light of the work conducted
by Dannenberg, Nedeltchev and Kübler on immune priming and cavitation, we won-
dered whether repetitive aerosol infection generated a different pattern of disease
from a single aerosol infection, even when the total bacillary exposure was the same
between groups. We found that repetitive aerosol exposure exacerbated both disease
and cavitation. This insight may have important ramifications for epidemiological
modeling of disease in high-incidence areas since cavitation is known to be a major
driver of disease transmission. Moreover, we characterized the rabbit response to
repetitive aerosol infection and showed that rabbits often developed multiple cavities
per lung. Therefore, a repetitive aerosol exposure protocol may be most appropriate
and efficient for pre-clinical studies investigating treatments to inhibit cavitation.
Mouse models
Mouse models of tuberculosis have been used for more than 50 years for understand-
ing pathogenesis and the development and evaluation of new tuberculosis drugs and
regimens58. The model is simple, inexpensive, tractable, and has the highest pre-
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dictive value for clinical efficacy of combination regimens of any preclinical model59.
Every drug regimen tested clinically for tuberculosis treatment in the 21st century has
been tested first in the mouse model60. Until recently, mice had been overlooked as
models of cavitary TB because commonly used mouse strains do not exhibit caseous
pathology after infection with M. tb. However, recent development of the C3HeB/FeJ
mouse model of cavitary tuberculosis provides a new model for studying cavities in
an animal model.
The susceptibility of C3HeB/FeJ mice to M. tb infection is determined pri-
marily at the sst1 locus, which regulates the macrophage innate immune response
to infection with intracellular pathogens61,62. Interestingly, C3HeB/FeJ mice are not
deficient in the activation of Th1 cytokine-producing T-cells or their migration to
the lungs63, macrophages in these mice have a reduced ability to control multipli-
cation of M. tb, with these cells preferentially undergoing cell necrosis rather than
apoptosis, associated with activation of the type-I interferon pathway and an ex-
aggerated host inflammatory response61,64. After infection with M. tb, C3HeB/FeJ
mice develop caseous lung lesions61, which are also known to be hypoxic65,66, and to
undergo calcification similar to human TB67. Initial reports of occasional cavitation
in C3HeB/FeJ mice66–68 led to further investigation of their potential as a cavitary
TB model. By using serial CT imaging, Ordonez et al. characterized pulmonary
cavitation in C3HeB/FeJ mice after aerosol infection with two M. tb strains69. Cav-
ities were observed in 47-61% of C3HeB/FeJ mice and the cavitation rate after M.
tb HN878 (East Asian lineage) infection (40%) was similar to that observed with M.
tb H37Rv (Euro-American lineage) (47%), although mice infected with HN878 were
more likely to require euthanasia prior to the first imaging time point. The cavities
observed shared features of human tuberculosis such as air-filled lesions with caseous
debris in various stages of liquefaction and mixed inflammatory cells lining the cavity
wall surrounded by encircling fibrosis. Unlike prior observations in rabbits, sensitiza-
16
tion with heat-killed bacilli prior to infection with M. tb HN878 (Beijing subfamily)
was protective in C3HeB/FeJ mice, leading to increased survival, lower pulmonary
bacterial burdens, and lower rates of cavitation during progressive disease and relapse
compared to un-sensitized animals. After treating the same mouse model with non-
curative combination chemotherapy, 11 of 18 (61%) mice developed cavities and were
significantly healthier than those that developed cavities in the context of untreated
infection, highlighting the potential for a chronic cavitary TB model69.
Similar to tuberculosis, where multiple lesion types may occur simultaneously
in lungs of patients with active disease58,70,71, lesions in various stages of development
with multiple different pathologies (pneumonia, necrosis and cavitation) have been
observed in C3HeB/FeJ mice, thus modeling lesion-specific progression of pathology
described in humans and NHPs14,69,72. These multiple lesion types provide an advan-
tage in the evaluation of tuberculosis drugs which are known to partition differently
into these lesions based on observations made in humans, mice and/or rabbits20,73–76.
Multinucleated giant cells and cholesterol crystals, characteristic of human tubercu-
losis lesions71, have also been observed in the C3HeB/FeJ model69.
The pathogenesis of tuberculosis cavities
The pre-cavity tuberculosis lesions
There is no consensus histologic origin of tuberculosis cavities. Observational studies
in tuberculosis patients are difficult since radiologic modalities are unable to reveal
the biochemical composition of water-dense regions and because tissue samples are
typically collected at a single time-point. However, defining the step wise pattern
17
of histologic events leading to cavitation is critical since these steps are translational
targets for the prevention of extensive lung destruction and disease transmission.
As discussed above, radiologic observations support the conclusion that tu-
berculosis cavities arise from pre-existing dense lung areas. In addition to cavities,
granulomas are well described in tuberculosis lung pathology and tuberculosis gran-
ulomas can be further attributed varying degrees of many different histologic charac-
teristics including lymphocytic infiltration, lipoid character, fibrosis, central necrosis
and liquefaction. Granulomas also appear in many different sizes from purely micro-
scopic lesions to grossly visible lesions that are the characteristic tubercular nodules
of a granulocytic pneumonia. In cases of more extensive lung disease, a large area
of immune infiltrate, found often at the apices of the lungs, can consume an entire
lobe and appear more similar to an abscess than a nodule. The pathogenic origins of
these abscess-like regions in tuberculosis are still debated, so it is possible that these
abscess-like areas are not simply large granulomas or the coalescence of multiple gran-
ulomas. For instance, Hunter proposes that morbidity in post-primary tuberculosis
arises from an obstructive lobular pneumonia rather than the enlargement of micro-
scopic granulomas71.
Only a fraction of radiographic dense foci undergo cavitation so specific chem-
ical and physical processes enable cavitation. One clue supporting the specificity of
these processes comes from experiments by Luna et al., who used serial CT scans
in a rabbit model of tuberculosis cavitation and found that small increases in the
central density of some tubercle lesions anticipated the development of cavities77.
Complementing these studies, histologic observations in rabbit models show that the
walls of cavities and necrotic granulomas are identical and that a cavitary focus is
derived from a necrotic granuloma that underwent removal of its central necrotic de-
bris. These studies also describe two specific histologic pre-cavity changes: extensive
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central necrosis and extracellular matrix depletion. It is possible that these two histo-
logic changes are responsible for the increase in density of pre-cavity lesions reported
by Luna et al.
Evidence of necrosis can be observed sporadically through the GPE region of
the cavity wall but the interface between the GPE region and the NL region is a
boundary of complete cell death that renders the contents of the NL region devoid
of live host cells. The mass of necrotic fragments in the NL region is described as
caseous necrosis because of its cheese-like consistency. One common misconception is
that liquefactive necrosis or liquefaction, a type of necrosis often observed in nervous
tissue, is necessary for the formation of a cavity. Some necrotic granulomas may
adopt the histologic identity of liquefactive necrosis, but observations in rabbits and
mice, where caseous necrotic debris is observed in the airways of cavitating necrotic
granulomas, show that liquefaction is not necessary for cavitation.
Depletion of the extracellular matrix in the lung also appears to be necessary
for cavitation. The robust extracellular matrix of the lung is the basis for the me-
chanical compliance and elasticity that resists force induced trauma. In cavities and
necrotic granulomas, pathologic matrix remodeling occurs throughout the GPE region
beginning with the effacement of the alveolar architecture and subsequent replace-
ment with fibrotic matrix. At the boundary between the GPE and the NL region, a
second and more dramatic depletion of extracellular fibrils is tightly coupled with the
boundary of extensive necrosis. The relative importance of matrix remodeling in the
GPE and its contributions to cavitation is unknown, but the importance of matrix
depletion at the GPE-NL boundary is paramount. Complete loss of extracellular ma-
trix causes irreversible damage to the lung. In the absence of an extracellular scaffold,
caseous necrotic debris can be evacuated with little mechanical resistance during the
formation of a cavity.
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The biochemical drivers of cavitation
The identity of the biochemical mediators of tissue destruction in tuberculosis re-
mains one of the greatest unresolved drivers of cavitation. If the primary mediators
of tuberculosis tissue destruction in necrotic granulomas are resolved then specific
pharmacological intervention provides an opportunity to prevent cavitation without
interfering with the beneficial aspects of the immune response78.
The epicenter of tissue destruction, the boundary of complete necrosis and
matrix-destruction between the GPE and the NL, is pathologically striking and caught
the attention of Dannenberg, Weiss, and colleagues in the 1960s. Dannenberg’s lab-
oratory performed experiments with ex vivo lung tissue from rabbits modeling tu-
berculosis lesions and showed that the necrotic debris within these lesions contained
factors capable of hydrolyzing proteins, DNA and RNA79–82. Dannenberg also iden-
tified the lysosome-resident protein cathepsin D as a possible mediator of extensive
tissue destruction83,84.
In the 2000s, Friedland, Elkington and others showed renewed interest in
the mediators of tissue destruction in tuberculosis85,86. Their hypothesis stated a
specific role for extracellular matrix destruction in the pathogenesis of cavities and
proposed host-expressed extracellular collagenases as the primary mediators of ex-
tracellular matrix degradation. This hypothesis was supported by transcriptomic
data from tuberculosis patients showing increased expression of matrix metwallopro-
teinases (MMPs) in tuberculosis lungs87–89. These results were further corroborated
by experiments in model systems. Volkman et al., determined that the zebrafish
homologue of human MMP-9 showed increased expression following infection with
Mycobacterium marinum90. Kübler and colleagues performed an RNAseq analysis on
tissue obtained from rabbits modeling tuberculosis pathology and found that tran-
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scripts from members of the MMP and cysteine cathepsin families of extracellular
proteases, specifically MMP-1, 12, 13 and cathepsin K, were enriched in the walls of
cavities56,91,92. Finally, Ordonez et al. used optical imaging to localize mouse MMP-9
to sites of lung destruction in C3HeB/FeJ mice69.
The MMP and cysteine cathepsin proteases are multi-membered conserved
protein families with convergent roles in tissue remodeling. The MMPs are a group
of 23 extracellular metallopeptidases that require zinc binding at their conserved cat-
alytic sites for activity93. Likewise, the cysteine cathepsins contain 11 members which
can be active in both lysosomal and extracellular environments94. Importantly, the
MMPs and cysteine cathepsins share important properties that support a role in tu-
berculosis lung pathology. First, their expression is highly controlled by the initial
translation of proenzyme forms requiring activation93,95, by optimal activity in the
extracellular environment, and by vulnerability to expressed inhibitory factors94,96.
Second, members of the MMPs and cysteine cathepsin peptidase families have sub-
strate specificity for elements of the lung extracellular matrix including collagen and
elastin97–100 . Finally, many of the transcriptional pathways that regulate MMP and
cathepsin expression are downstream of immune-system receptors, suggesting that
the expression of these proteases can be regulated in response to changes in the local
inflammatory response101–104.
Significant work is still necessary to clarify the role of extracellular proteases
in tuberculosis pathology. First, the primary mediator or mediators of matrix de-
struction must be identified. Encouragingly, Rojas-Espinosa et al., Kübler et al., and
Volkman et al., all separately identified members of the MMP and cysteine cathepsin
protease families as likely mediators of tissue destruction, defining important targets
for future investigations84,90,91. Second, the consequences of matrix remodeling in
the GPE must be weighed against matrix depletion at the GPE-NL boundary. It is
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possible that irreversible tissue damage occurs well in-advance of matrix depletion
but under the guise of pathologic fibrosis. Finally, a major challenge for researchers
will be to discern whether the action of extracellular proteases can be uncoupled from
the spatially co-incidental necrosis front. Matrix breakdown may be an accidental,
though dangerous, consequence of the robust cell death that occurs at the GPE-NL
boundary, whereby dying cells release a milieu of normally sequestered proteolytic
factors into the extracellular environment.
The biophysical drivers of cavitation
Although matrix destruction and caseous necrosis are necessary for cavitation, they
are not sufficient. In radiology studies, numerous dense inflammatory foci appear but
do not cavitate. Furthermore, in tissue sections from human and modeled tuberculosis
lungs, large caseous, but not cavitary lesions are also common. Therefore, it is likely
that factors other than biochemical mediators also help determine the likelihood that
a caseous lesion becomes a cavity. Here, we review the biophysical factors that likely
play a role in cavitation.
One possible determinate is proximity to an airway. In this explanation,
caseous tubercles that do not breach an airway fail to cavitate because they can-
not evacuate their caseous contents into the bronchial tree. This hypothesis predicts
that larger lesions are at a greater risk of cavitation since they are more likely to
connect to an airway but does not explain why large caseous foci often exist but do
not cavitate. To explore this heterogeneity, Nagasawa et al., undertook a series of
autopsy studies in which the investigators created plastic casts of cavities and their
draining bronchi105. Their work found a relationship between cavity-size and total
bronchial drainage. An absolute minimum diameter of 0.3 cm was necessary for the
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drainage of small cavitites, but larger cavities were drained by multiple, often larger,
bronchi. Based on these observations, it is likely that some caseous foci enlarge but
do not cavitate because they do not encounter bronchi that match the relative size
necessary for cavitation.
Pressure may be another driver of cavitation. Working in separate models,
Ihms and Urbanowski (unpublished) in rabbits and Ordinez et al., in C3H3B/FeJ
mice, noticed that small newly formed cavities often had a smooth surface at the in-
terface between the necrotic debris and the cavity space, reminiscent of a gas bubble69.
These findings were corroborated by studies on cavity morphology in tuberculosis pa-
tients106. We propose that these observations are best explained by a check-valve
mechanism where small amounts of caseum initially block the draining bronchus. In-
spiration creates negative pressure within a micro-cavity that allows small amounts
of air to pass the check-valve. Relaxation of the respiratory muscles traps air in a
positive-pressure bubble within the micro-cavity. During subsequent inspirations it
is energetically favorable to reduce the negative pressure within the micro-cavity by
evacuating more caseum to enlarge the cavity. This hypothesis also explains the dy-
namic wall thickness of thick-walled cavities which varies as caseum drains through
the bronchus.
A positive-pressure model may explain the earliest cavitation events, but sev-
eral observations argue against it as the penultimate model for cavity growth. First,
many tuberculosis cavities, in humans and models, do not have a gas-bubble like ap-
pearance. Moreover, many large cavities have open connections between the cavity-
space and the draining bronchus. Therefore, the mechanism of large-cavity growth is
also unknown and requires further investigation. Ihms and Urbanowski et al., under-
took a study of cavity dynamics in a rabbit aerosol model of cavitation (unpublished)
and concluded that the pull of lung tissue at the periphery of the cavity wall likely
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aides during cavity formation and growth. Finally, it is also possible that a continu-
ous cycle of matrix breakdown, necrosis, and caseum expulsion within the cavity wall
leads to cavity enlargement.
We are unaware of any recent studies that attempt to describe cavities in a
physical model, but we propose this as an important area of research. A biophys-
ical model of tuberculosis cavities would allow researchers to integrate tissue-level
biochemical changes as physical constants that contribute to cavity formation and
enlargement. This approach will also require a collaborative team of biophysicists
and experimental biologists.
Microbial drivers of cavitation
A cavity is not pathognomonic for M. tb infection and numerous bacterial and fungal
pathogens are associated with cavitation. However, M. tb does cause the highest rate
of cavitation among infectious pathogens. One possible explanation for this is that M.
tb’s success in aerosol transmission is directly tied to its ability to become aerosolized
via the bronchial-cavity space. In this perspective, M. tb evolved to cause a pathologic
inversion of anatomical topology where the internal space of the granuloma becomes
continuous with the air in the environment.
If M. tb evolved to cause cavities, then specific virulence factors of the M.
tb bacillus must drive cavitation. Yamamura and colleagues investigated the cavity-
inducing properties of purified components of the mycobacterial cell wall. In their
experiments, the investigators noted that cavities could be caused by trans-thoracic
injection of milligram quantities M. tb cell wall lysates directly into the lungs of
rabbits50. To identify the cavity-causing elements of M. tb, they purified the protein
fraction from the lipid fraction of the M. tb cell wall. Next, the investigators injected
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these fractions into the lungs of rabbits. Yamamura et al., found that if injected alone,
both the protein and lipid fractions caused granulomas, but when injected together
were they able to reconstitute the cavity-causing effect of M. tb lysates.
Yamamura et al., also injected lysates from BCG, an attenuated laboratory
strain derived from Mycobacterium bovis, and Nocardia rubra (a bacterial species in
the same order as mycobacteria) and found that these injections were able to cause
granulomas51. When injections with these lysates were complemented with the M.
tb protein fraction, then cavity formation occurred. These observations suggest that
some protein factor, not present in BCG or Nocardia rubra, is an inducer of cavitation
in M. tb infection. Therefore, immunogenic proteins including ESAT6 and CFP10,
encoded by genes of the RD-1 locus of virulent M. tb, but lost from the BGC genome,
are obvious candidates107.
Finally, Yamamura and colleagues also studied the cavity-inducing properties
of the lipid fraction of the M. tb bacillus52. Trehalose dimycolate is the most prevalent
glycolipid found in the M. tb cell wall and Yamamura et al., found that trans-thoracic
lung co-injection of trehalose dimycolate and the M. tb protein-fraction in a mixture
was able to cause cavities. Elegantly, Yamamura resolved the minimally effective
structure for cavity induction by substituting trehalose dimycolate with synthetic
fatty-acids. Only synthetic species with long branched-chain fatty acids were able to
substitute for trehalose dimycolate to cause cavities.
Taken together, Yamamura and colleagues showed that the molecular composi-
tion of the M. tb cell wall contains lipid and protein factors that confer cavity-causing
specificity to virulent M. tb strains. However, Yamamura’s work did not identify
the pathways modulated by these virulence factors. To date, no investigators have
reported intrinsic molecules of M. tb that are capable of directly mediating tissue
destruction. Therefore, in careful consideration of Yamamura’s seminal work, we hy-
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pothesize that M. tb infection leads to a high rate of cavity formation by two comple-
mentary pathways. First, the protein fraction leads to the acquisition of cell-mediated
immunity and the recruitment of lymphocytes to drive granuloma enlargement. Sec-
ond, the lipid fraction provides a digestion-resistant substrate that accumulates in
the endocytic compartment of phagocytes and acts as a stress-inducing factor for in-
nate immune cells108. Necrosis, matrix breakdown, and cavity formation is driven by
the summative effects of pro-inflammatory cytokines from recruited lymphocytes act-
ing on lipid-stressed cells. There is also likely overlap between these pathways since
ESX1 secreted proteins are known to cause macrophage activation and death while
trehalose dimycolate similarly stimulates cytokine secretion and may act to prime
T-cell immunity109. This model requires further interrogation and validation.
Immunological drivers of cavitation
Strong evidence implicates the adaptive immune response as a major driver of cav-
itation. HIV patients with low CD4+ counts cavitate less often than patients with
intact immune systems110. Furthermore, antigens that elicit a T-cell response appear
to be highly conserved in virulent strains of M. tb111. Finally, the CD4+ Th1 response
effectors are strongly tied to tuberculosis control in humans and TB models.
The generation of a T-cell response in tuberculosis is mediated by the acti-
vation of antigen-presenting cells that migrate to draining lymph-nodes. Subsequent
expansion and homing of reactive Th1-polarized T-cells to existing granulomas forms
the lymphocytic cuff commonly observed around necrotic granulomas and cavities.
T-cells at granulomas produce the soluble pro-inflammatory cytokines IL-2, IFN-γ,
and TNF-α.
We propose a model in which the adaptive immune response to M. tb infection
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acts as a pro-inflammatory switch with three effects that drive cavitation.
1. T-cell derived pro-inflammatory cytokines IFN-γ, and TNF-α activate macrophages
and neutrophils in an attempt to kill M. tb bacilli. Cells near the center of
the granuloma experience the highest concentrations of pyogenic cytokines and
these signals cause a state of stress on innate immune cells that promotes necro-
sis at the center of the lesion.
2. T-cells provide signals to recruit and activate circulating monocytes to gran-
ulomas. Since vascular elements are intact within the GPA but not the GPE
regions, inflammatory cells must traverse the GPE region, homing along pyo-
genic cytokine gradients, toward the border of the NL. Migrating monocytes
secrete matrix-degrading enzymes to allow movement through tissue matrix so
the influx of immune cells may be the major driver of tissue matrix weakening
and depletion within the GPE region.
3. The cumulative effects of immune-cell activation and T-cell recruitment in-
creases the oxygen demand of the granuloma and causes a hypoxic environment
at the center of the granuloma and this hypoxia, in-turn, drives central necrosis.
Mycobacterial ecology inside the cavity
One of the most intriguing perspectives on cavitation considers the internal surface of
the cavity as a unique mycobacterial ecosystem. In 2003, Jacques Grosset reviewed
the pathogenesis of tuberculosis and clarified the most dangerous pathologic develop-
ment: extracellular bacteria at the cavity surface17. Corroborating this assertion, Ors
et al. found that the thickness of the cavity wall in tuberculosis patients correlated
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with the degree of smear positivity3. Indeed, in both human studies and tuberculo-
sis models, the caseum lining the cavity wall supports mycobacterial blooms with as
many as 109 bacilli per cavity14,112. The caseum of the cavity contrasts with non-cavity
lesions where M. tb bacilli concentration is heterogeneous and often undetectable14.
The internal surface of the cavity is the anatomical site with the highest con-
centration of mycobacteria. Several factors support extensive bacterial replication
within the cavity.
1. The formation of a cavity dissipates anoxia, so oxygen may be the
limiting resource for bacterial proliferation within the lung113. Dur-
ing in vitro studies, the change from an anoxic to oxygen-rich environment
increases the doubling time and the concentration of bacteria achieved during
the stationary-phase. Similar changes in growth kinetics probably occur within
the caseum after a cavity forms.
2. The caseum inside the cavity is immune-sheltered substrate, so bac-
terial replication is unchecked by phagocytes and neutrophils.
3. The wall of the cavity reduces the penetration of many anti-mycobacterial
agents so that suboptimal concentrations chemotherapeutic drugs
reach the replicating bacteria in the caseum.
The superposition of high bacterial concentration with the potential for aerosoliza-
tion has important clinical implications. In the pre-antibiotic era, surgical lung col-
lapse therapy showed efficacy as a therapy for extensive pulmonary tuberculosis. More
recently, Corbetta et al. used endobronchal one-way valves to cause regional hypoven-
tilation and saw improvement in cavitary disease114. These observations implicate
oxygen tension within a tuberculous cavity as a major factor governing the progres-
sion of cavity disease.
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The cavity also provides an environment for genetic diversification and the
acquisition of drug resistance among mycobacteria proliferating in the necrotic de-
bris115. Kaplan et al. compared the genomes of M. tb isolates from lung resections
and found that the explosive replication at the cavity wall led to heterogeneity at
drug-resistance determining loci18. In a clinical setting, the delivery of suboptimal
anti-mycobacterial drug doses to the caseum may enrich for drug-resistant mutants.
Many aspects of microbial ecology within the cavity remain unstudied, proba-
bly because of the difficulty in modeling tuberculosis cavities and obtaining specimens.
However, with the recent advances in modeling cavities, it may now be possible to
conduct detailed studies on bacterial physiology and growth state within cavities.
For instance, transcriptional and proteomic studies on bacteria in caseum may help
resolve conserved metabolic pathways necessary for proliferation in necrotic debris.
Bacterial community architecture may also be organized in three dimensions, with a
reservoir of progenitor bacteria near the GPE-NL boundary where they are protected
from the constant sloughing of caseum.
Healing of tuberculosis cavities
Destruction of the tissue extracellular matrix, fibrosis, and cavitation all cause ir-
reversible damage to the lung. In autopsy cases from the pre-antibiotic era, the
most common incidental finding consistent with healed tuberculosis was apical scar-
ring, suggesting that the destroyed alveolar architecture of the lung is never replaced.
Cavities may also persist for years after tuberculosis is cured and can become sites for
opportunistic infections. Unfortunately, few treatment options exist for tuberculosis
cavities. In this section, we review the small body of literature describing healing
reactions and tuberculosis cavities.
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Amberson followed 476 patients with cavitary tuberculosis in the pre-antibiotic
era and found that only about 5% of cavities larger than 2 cm became radiologically
invisible during prolonged observation116. In the remaining fraction of patients, about
30% of cavities shrank, and 65% remained the same size or enlarged. These percent-
ages are likely changed following successful cure with antibiotics, since Ross and Kay
later found that the majority of persistent tuberculosis cavities continued to have
mycobacteria within the wall117. Following a series of pathology studies on chronic
cavitary disease, Hermel and Gershon-Cohen proposed two mechanisms of cavity heal-
ing. In closed healing cavities resolve to scar tissue while in open healing, the wall
of a cavity becomes extensively fibrosed and remains as an open structure within the
lungs106
Significant efforts must still focus on the treatment of cavities. Open-healing
of cavities is not ideal because cavities can later host opportunistic infections118. One
therapeutic goal is to prevent the enlargement of existing cavities. Several treatment
strategies are under investigation. First, Corbetta et al. explored the use of endo-
bronchial one-way valves to reduce the concentration of oxygen within the cavity.
The reduced oxygen concentration likely hinders bacterial growth and prevents fur-
ther necrosis and matrix breakdown114. Another potential strategy is to treat with
aerosolized antibiotics to dramatically reduce bacterial burden within the cavity74.
These treatment paradigms require further investigation.
The ultimate goal of tuberculosis cavity treatment should be to replace the
cavity with functional pulmonary tissue. This goal poses significant technical chal-
lenges to regenerative medicine since the lung is composed of a complex tree of alveoli,
bronchi and blood vessels created in the context of the developing fetus119.
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A Foreword to the Dissertation
A tuberculosis cavity is the epicenter of advanced tuberculosis. Unfortunately, cavities
are also one of the least-studied aspects of tuberculosis. In this review we describe
the known processes that drive cavitation. The core elements of cavity pathobiology
are a perfect storm of host and microbial factors that drive tuberculosis transmission
and damage the lungs. We also reviewed recent advances in modeling cavities. Our
goal is to provide researchers with a better understanding of the tools available for
studying cavities and that these tools will be applied during research efforts to reduce
morbidity and mortality in tuberculosis.
In the manuscript that follows, we present studies that advance our under-
standing of the mechanism and inhibition of cavitation in tuberculosis. Chapter 1
details a retrospective study conducted at the Chesney Medical Archives of the Johns
Hopkins University. The study reviews 3,000 autopsies where evidence of tubercu-
losis was appreciated by pathologists working in the pre-HIV/AIDS era. The goal
of this investigation is to describe the pathologic phenotype of extensive lung de-
struction in tuberculosis. Chapter 2 describes the challenges of modeling extensive
lung destruction in tuberculosis and introduces a novel rabbit model for investigating
lung destruction and cavitation in tuberculosis. Chapters 3 and 4 focus on identify-
ing the biochemical drivers of cavitation (reviewed above). In chapter 3 we applied
the repetitive aerosol rabbit model, characterized in chapter 2, to test the effects
of pharmacological inhibition of the collagenase MMPs during cavity formation. In




The prevalence of cavitation
among cases of active tuberculosis
Michael E. Urbanowski · Marjorie Kehoe
“The tragedy is not that things are broken.
The tragedy is that things are not mended”
by Alan Paton.
Cry, The Beloved Country (1948)
1.1 Introduction
Cavitation is a well-described consequence of tuberculosis, but accurate estimates for
the prevalence of cavitation among cases of active tuberculosis are rare. The textbook
Tuberculosis (2004) provides the estimate of between 19 and 50%4. In their 2003
study, Gomes et al. reported that 36% of 153 patients in a retrospective radiographic
study had lung cavities11. Differences in the modality used for cavity identification,
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the characteristics of the survey population, and the most prevalent strain of M. tb
in the study population likely contribute to discordance among estimates120. For
instance, it is well established that low CD4+ cell counts are associated with lower
rates of cavitation in cases of HIV/M. tb co-infection110. Therefore, a study describing
a population with high rates of AIDS may find a lower prevalence of cavitary disease
than a study describing a population with low rates of AIDS. Alternatively, survey
populations taken from inpatients at hospitals may be enriched for cases of severe
tuberculosis and therefore more likely to develop cavities.
Despite the difficulty in determining the prevalence of cavitation in tuberculo-
sis, the estimate may be critical for computational models of disease transmission121.
In their seminal study, Riley et al. noticed that only two individuals were respon-
sible for the vast-majority of transmission events on a tuberculosis ward13. Riley et
al.’s study and those of others confirm the epidemiological importance of tuberculosis
super-spreaders122. Super-spreaders are individuals who are more likely to spread
tuberculosis among the larger population with tuberculosis123. For tuberculosis, it
is estimated that about 20% of cases of active tuberculosis contribute to 80% of
transmission events124.
The pathologic phenotype that enables super-spreaders is likely the presence
of a cavity. This is a physically plausible hypothesis since cavitation in tuberculo-
sis causes high concentrations of mycobacteria to be continuous with the external
environment via the bronchial tree. Further supporting this hypothesis, Bailey et
al. developed a predictive model for skin-test conversion among close contacts of
newly diagnosed cases of tuberculosis16. The investigators found that the probability
of skin-test conversion for contacts of individuals with cavitary disease was 0.670,
the highest probability of any factor involved in the study. This study is supported
by case-studies of tuberculosis super-spreaders with confirmed cavitary disease125,126.
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Therefore, the prevalence of cavitary disease could be used to directly inform compu-
tational models about the prevalence of super-spreaders.
This chapter focuses on resolving the prevalence of cavitation among cases of
active tuberculosis. To accomplish this goal, we received institutional review board
permission from the Johns Hopkins University Chesney Medical Archives to create
a database of tuberculosis autopsy cases. This database contains the major patho-
logic findings associated with 3000 autopsy cases where evidence of tuberculosis was
reported between 1920 and 1950. To our knowledge, this is the largest retrospective
cohort of tuberculosis autopsy cases where the entire set of non-biased pathologic
findings is reported. These years were selected because they correspond to a time pe-
riod when established terminology was used to describe autopsy findings consistent
with tuberculosis but was before the use of antibiotics or the HIV epidemic, both of
which are known to change the frequency of cavitation. Therefore, we report on the
prevalence of cavitation among individuals with active tuberculosis at autopsy during
the pre-antibiotic era.
Our findings reveal the prevalence of lung cavities among cases of active tuber-
culosis to be 15%. As part of our studies, we also generated a de-identified database
of autopsy cases. Each autopsy case in the database is reconstructed with the full
set of associated pathologic findings. Finally, we restructured the database using
standardized terminology and an imposed inheritance hierarchy schema that enables
comparisons between all phenotypes within the database. Our goal is to release this
database as a tool to the tuberculosis research community.
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1.2 Results
1.2.1 Construction of a database for tuberculosis autopsies.
Autopsies at the Johns Hopkins Hospital between from the years 1920 through 1950
were previously indexed by pathologists. These indexes defined a set of 159 patho-
logic findings associated with tuberculosis. Each index entry for a pathologic finding
listed the autopsy case numbers that demonstrated the finding. The entire index for
autopsies between 1920 – 1950 corresponded to approximately 3000 autopsies.
The 159 pathologic findings identified in the indexes were a set of non-standard
terminology. This non-standard terminology was discordant for several reasons.
1. Variations on the terms used for pathologic findings were used by different
pathologists to describe similar findings. From this dataset, an example of this
inconsistency is the use of the term “lung tubercle” and “lung nodule”.
2. Some pathologic findings represent compound findings while others represent
single findings. From this dataset, an example of this inconsistency is use of the
term “lung cavity with tubercles” and “lung tubercles” and “lung cavity.”
3. Pathologists used different terms for pathologic findings during different periods
of time. From this dataset, an example of this inconsistency is the use of
the term “pediatric tuberculosis” which was indexed as a separate category of
tuberculosis starting in the years 1927 — 1936 and may reflect the terminology
preferences of a single pathologist.
The discordance in terms used for tuberculosis-associated pathologic findings
reduced the ability to make comparisons among autopsy cases in the database. There-
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fore, we created a modified version of the database with three major changes to the
data architecture (Fig 1.1).
1. To rectify the variability in terminology we developed a set standardized patho-
logic terms and aggregated groups of autopsy cases indexed under synonymous
terms into the same category (Fig 1.1C).
2. To rectify the use of compound terminology we generated a hierarchy that al-
lowed compound terms to be inherited by non-compound terms. This hierarchy
reflected both the architecture of the indexes and our knowledge of associ-
ated findings in tuberculosis pathology. For instance, autopsies where extrapul-
monary disease was found were further indexed by the organs where pathologic
changes were identified. In our hierarchy we created a master category of “ex-
trapulmonary disease” and sub-categories for each organ. The autopsy cases
listed in each organ sub-category inherited back to the master category “ex-
trapulmonary disease” so that comparisons could be made between both the
prevalence of organ-specific dissemination and between the prevalence of extra-
pulmonary disease and other findings (Fig 1.1C, Fig. 1.2)
3. To rectify the use of different pathologic terms during different periods of time
we generated histograms of term-usage by year. We restricted out comparisons
to years when terms were in use.
The complete list of findings and associated autopsies were deconvoluted using
an Excel algorithm that re-associated each case with a binary matrix of findings. The
result of iterating the deconvolution algorithm over the entire set of autopsies was a
2-dimensional matrix of autopsies and associated pathologic findings (Fig 1.1A and
B).
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Dataset restructuring to promote comparisons between pathologic
phenotypes
Figure 1.1: Methods of restructuring the tuberculosis autopsy dataset to promote comparisons
between pathologic phenotypes. (A) Pattern of deconvolution. Data was received from the autopsy-
record index as a set of pathologic findings and associated autopsy numbers. The Excel algorithm
in B was applied to each column in the deconvoluted matrix to generate a 2-dimensional matrix
of autopsy cases and their associated pathologic findings. (B) The Excel algorithm used in A. (C)
An example of the creation of a dataset architecture with standardized terminology for pathologic
findings. Top row shows an example architecture as copied directly from the autopsy index. Bottom
row shows a hierarchial architecture created from the top-row dataset. Autopsy cases can appear in
multiple categories. All higher categories inherit cases from connected lower categories.
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1.2.2 The prevalence of tuberculosis cavities among cases of
active tuberculosis was 15%
We filtered autopsy records from our 2-dimensional matrix for cases of active tuber-
culosis. Next we further selected autopsies for which we had looked at the original
autopsy record and collected demographic data (age, gender, year-of-death) and had
confirmed that the case was indexed correctly (Fig 1.3). Evidence of tuberculosis was
found in 18% of all autopsies performed. These filters resulted in 844 autopsy records.
Next we further filtered our 844 autopsy set for cases of active tuberculosis. We de-
fined “active tuberculosis” as clinician-assessed tuberculosis described in the clinical
notes before the time of death and where pathologists confirmed pathologic changes
consistent with tuberculosis at autopsy. Therefore, it is possible that tuberculosis
was not the primary cause of death for some of these autopsy cases, but was rather
a co-morbidity. We found 337 autopsy cases of active tuberculosis corresponding to
40% of the autopsies where evidence of tuberculosis was found (Fig 1.3A).
The frequency of cavitation among the 337 autopsy records of active tubercu-
losis was 15% among active TB cases and 6.6% among all autopsies where evidence
of tuberculosis was found (Fig 1.3B). We also report the frequency of several other
common pathologic findings in our dataset as a percentage of all TB cases in the
database and as a percentage of active TB cases (Fig 1.3B).
1.2.3 Cavities were most common in the age-range 45 — 55
years.
The most common age of cavitary tuberculosis may also inform computation models
of transmission. For instance, it is unlikely that an infant with cavitary tuberculosis
will have the same number of contacts as an individual who is 20 years old. Since we
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know the age-of-death for autopsy cases in our database, we generated a prevalence
histogram of cavities by age (Fig 1.4C). However, we noticed that the same histogram
applied to all autopsy cases with active tuberculosis had a peak in the age range 0 —
5 years, indicating that more autopsies were performed on infants (Fig 1.4B). There
are two likely reasons for this peak:
1. The prevalence of tuberculosis among children in the age-range of 0 — 5 years-
of-life is higher than for other age groups.
2. The selection of cases for autopsy was biased toward infants.
To assess the frequency of cavities in each age group, we divided the prevalence
of autopsies with cavities in each age group by the prevalence of autopsies with active
tuberculosis in each age group. The resulting histogram showed that children between
the ages 0 — 5 years do not have an increased prevalence of cavitation (Fig 1.4D).
Rather, there was a peak in the prevalence of cavitation in the age-range 45 — 55
years of age.
1.2.4 “Case complexity diagrams” display the relative het-
erogeneity and complexity of autopsy cases with cavi-
tary disease.
The 2-dimensional matrix of autopsy records contains higher-order phenotype pat-
terns. To begin analyzing these pattern, we first asked about the relative prevalence
in non-cavitary tuberculosis findings among cases of cavitary disease and non-cavitary
disease (Fig 1.5). Our analysis showed that the prevalence of select pathologic find-
ings was similar between cavitary and non-cavitary tuberculosis groups. The one
exception was the presence of “tubercles” which had a higher prevalence in cavitary
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tuberculosis than non-cavitary tuberculosis. To further understand these patterns we
create a “case complexity diagram” (Fig 1.6). This diagram begins with an initial
phenotype, in our example, cavitary tuberculosis. Cases are then clustered based
on the binary presence or absence of cavitary disease. Along the x-axis are a set of
arbitrary steps of case-complexity. After the initial grouping of cavitary disease from
non-cavitary disease, we next searched for the next most prevalent pathologic finding
in each subgroup. The algorithm was iterated for each subsequency sub-group over
7 levels of complexity.
The case complexity diagram shows that the findings of extrapulmonary dis-
ease in combination with lymphadenopathy and primary tuberculosis was the most
common phenotype associated with both cavitary and non-cavitary disease. Tuber-
cles were the only trait consistently enriched among cavitary tuberculosis. Finally,
lung fibrosis was only found in cases of non-cavitary tuberculosis, though we are less
confident about this conclusion since the number of individuals with fibrosis in the
non-cavitary tuberculosis group was low.
1.3 Discussion
In this chapter we describe the creation of a dataset containing the complete patho-
logic phenotypes of 3000 cases with autopsy findings consistent with tuberculosis.
We structured the dataset with standardized terminology for each discrete pathologic
finding at autopsy and created an inheritance hierarchy for compound terminology.
Finally, we used this dataset to provide a robust estimate for the prevalence of cav-
itation among all cases of active tuberculosis at autopsy. We report this prevalence
as 15%. We also investigated the age distribution of cavitary disease and show that
the rate of cavitation is roughly the same until the age range 45 — 55 years. These
40
findings may inform computational models of tuberculosis transmission by identify-
ing super-spreaders. Importantly, the prevalence estimate of 15% and the associated
age-specific prevalence estimates may overestimate the prevalence of cavitary disease
since they are taken from hospital autopsy cases. The estimate of 6.6% prevalence
of cavitation among all autopsies where tuberculosis pathology was found may be
a better estimate for the prevalence of individuals with cavitary tuberculosis in the
community.
The dataset contains higher-order patterns. As an example of a higher-order
description of this dataset, we created a “phenotype complexity diagram” which shows
the relative prevalence of each phenotypic trait associated with cavitary and non-
cavitary tuberculosis. As part of this analysis, we noted that a greater prevalence of
tubercles was specifically associated with cases of cavitary tuberculosis. We hypoth-
esize that the extent of tubercules due to granulomatous pneumonia may correlate
with risk for cavitation since more tubercles increase the chances of bronchial asso-
ciation. This hypothesis requires further investigation. It is possible that repetitive
exposure leads to a phenotype where tubercles are prevalent throughout the lung
and this prevalence increases the risk of cavitation. Chapter 2 of this manuscript
addresses the influence of repetitive exposure on disease progression and cavitation.
We believe that this dataset could be useful to other investigators. Our in-
























































































The prevalence of pathologic findings among cases of tuberculosis.
Figure 1.3: The prevalence of pathologic findings among cases of tuberculosis determined at au-
topsy. (A) Chart showing relative number of autopsy cases where findings consistent with tuber-
culosis were determined at autopsy compared to the prevalence of active tuberculosis cases in the
same dataset. (B) Prevalence of various pathologic findings compared between the two groups in A.
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The age distributions of tuberculosis autopsy cases.
Figure 1.4: The age distributions of tuberculosis autopsy cases. Binning was in 5-year increments
(A) Prevalence by age of all autopsies with evidence of tuberculosis. This histogram is composed
of 844 unique autopsy records. (B) Prevalence by age of all cases of active tuberculosis. This
histogram is composed of 337 unique autopsy recoreds. (C) Prevalence by age of cavities among
cases of tuberculosis. This histogram is composed of 96 unique cases of cavitary tuberculosis. (D)
Prevalence by age of cavities among cases of tuberculosis standardized to the prevalence of active
tuberculosis in each age group. For all histograms “ND” indicates “No Data.”
44
Pathologic findings associating with cavitary and non-cavitary
tuberculosis
Figure 1.5: Prevalence of pathologic findings among autopsy cases with and without lung cavities.










































































































































































































Repetitive aerosol exposure to
model tuberculosis cavities
Michael E. Urbanowski · Elizabeth A. Ihms · William R. Bishai
“But at this point his life took the following
turn. He had had to work hard and steadily
for his examination, and had come home
looking rather paler than a man of his blond,
rosy type should do. Dr. Heidekind scolded,
and insisted on a change of air; a complete
change... it was that Hans Castorp should
go for a few weeks to the high mountains
before he took up his work in the yards.”
by Thomas Mann.
The Magic Mountain (1924)
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2.1 Introduction
Tuberculosis is a major cause of morbidity and mortality with 10.4 million new cases
of tuberculosis and 1.4 million deaths in 2015127. Individuals with extensive lung
disease develop a spectrum of gross lesions including diffuse inflammation, tubercles,
caseous tubercles, and cavities. The most consequential of these lesions is the lung
cavity.
Cavities are not specific to tuberculosis, but they are the greatest risk fac-
tor for transmission of bacilli2,16,17,19. Cavitary tuberculosis is also more difficult to
treat than non-cavitary tuberculosis and is associated with the emergence of drug-
resistance18. For patients with cavitary tuberculosis who are cured, the cavities may
remain, offering a niche for other opportunistic infections25. Cavitary lesions that do
resolve are associated with fibrotic scarring and chronically diminished pulmonary
function24,128 .
A perfect storm of pathologic features coincide within cavities to drive trans-
mission and a reduced likelihood of treatment success. The interior surface of the
cavity wall represents an immune sanctuary that permits high levels of extracellular
bacterial proliferation14,18. Moreover, cavities often communicate with the conducting
airways of the lung, providing a physical conduit for aerosolization and transmission
of M. tb bacilli27. Finally, diminished vascularity and widespread necrosis within the
cavity wall reduces the penetration of chemotherapeutic drugs20–22,129.
Despite the importance of cavities to the natural history of tuberculosis, the
mechanism of cavity formation in tuberculosis remains unclear. Histologically, cavi-
ties are thought to arise from necrotic granulomas, whose centers are both devoid of
extracellular matrix. Pulmonary extracellular matrix is composed primarily of col-
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lagen and elastin, which provide mechanical support to the lung while maintaining
compliance and elasticity. The expression of collagenases leads to caseation, suggest-
ing that matrix depletion may be an early mechanistic driver of cavitation84,86,130.
Indeed, increased expression of collagenases is also associated with cavity formation
in both animal models and tuberculosis patients87,131 .
A limitation to studying tuberculosis cavitation is the lack of reproducible an-
imal models26,132,133. Mice and guinea pigs rarely develop cavities while they do occur
in non-human primate and rabbit models. Previous studies employed pre-sensitization
with heat-killed tubercle bacilli together with a high-dose aerosol challenge, transtho-
racic challenge, or intrabronchial instillation53–55. While these methods result in cav-
itation in some animals, they also generate extensive pneumonitis making it difficult
to monitor granuloma formation, necrosis and progression to cavity formation.
Here we describe a novel rabbit model for cavitary tuberculosis based on repet-
itive aerosol exposure. This model reliably generates multiple cavitary foci in 60 —
80% of study animals in a short period of time. Compared with single exposures of the
same total bacterial burden, repetitive exposure generated more advanced disease and
more cavitary foci, suggesting that repetitive exposure to aerosolized bacilli may be
an important determinant for the severity of tuberculosis in high-incidence settings.
Coincidentally, the number of exposures experienced by newly infected TB patients
was recently reported as a risk factor for disease progression134. We also confirmed
that this model develops human-like tuberculosis cavities where matrix depletion was
a pathologic feature of cavity development.
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2.2 Results
2.2.1 Repetitive aerosol exposure to M. tb causes a high fre-
quency of cavitation in a rabbit model
Previous investigations suggested that sensitization with heat-killed mycobacteria
prior to infection increased the frequency and severity of cavitation in rabbit mod-
els55,56. We reasoned that multiple aerosol challenges with virulent M. tb would pro-
vide a robust sustained immune-sensitizing effect while simultaneously antagonizing
both the innate and adaptive defenses.
To test this hypothesis, we conducted a limited-power study by exposing rab-
bits to M. tb in two different patterns. For our studies we defined exposure as the
product of the bacterial concentration in the aerosol inoculum and the total time
spent in the aerosol chamber. One group of rabbits received five aerosol challenges
with M. tb at a constant exposure of OD600 0.05 spread evenly over a two week pe-
riod. A second group of rabbits received a single aerosol challenge with M. tb where
the aerosol exposure was OD600 0.25, or five times that of a single exposure in the
repetitive exposure group (Fig 2.1A). These challenges corresponded to an extrapo-
lated day-1 bacterial implantation of 400 CFU per exposure in the OD 0.05 group
and 2200 CFU per exposure in the OD 0.25 group (Fig 2.2). We confirmed that the
cumulative exposure was the same for both groups by measuring the colony-forming
units in the aerosol inoculum (Fig 2.1A).
To address the possibility that the infection chamber does not achieve aerosol
concentrations of bacilli that are linearly correlated with the optical density of the
aerosol inoculum, we performed a titration assay to compare the optical density of
the aerosol inoculum with the day-1 implantation of bacteria in rabbit lungs, and
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The pattern of repetitive aerosol exposure and disease outcomes
Figure 2.1: Infection parameters and disease patterns for rabbits challenged in the single and
repetitive exposure groups. (A) Experimental exposure conditions and timing. Single exposure group
rabbits received a single implantation with approximately 2500 bacteria on day 8 and sham exposures
on days 1, 4, 12 and 16. Repetitive exposure group rabbits received five repetitive exposures resulting
in implantation of approximately 500 bacteria on each of days 1, 4, 8, 12 and 16. Exposure was
calculated based on the CFU in the aerosol inoculum. The repetitive exposure was calculated as
the sum of the CFU/mL on each day of infection. (B) Frequency of cavitation among rabbits in
the single and repetitive exposure groups. (C) The number of cavities per animal in the single
and repetitive exposure groups. Cavity counts are only plotted for the animals that demonstrated
cavitation. (D) Quantification of the fraction of lung identified as diseased by gross observation for
rabbits in the single exposure and repetitive exposure groups.
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showed a linear correlation in the optical density range used in these experiments
(Fig 2.2). Based on this titration assay, Equation 2.1 relates the optical density of
log-phase harvested inocolum to the recovered day-1 bacillary implantation in rabbit
lungs. Equation 2.2 also relates the optical density of log-phase harvested inoculum
to recovered day-1 implantation, but where data-points used to generate the standard
curve are corrected for tissue-mediated CFU signal depression caused by plating onto
agar with high concentrations of lung homogenate. The tissue-mediated CFU signal
depression factor was calculated to be 9.63 ± 1.29. Equation 2.3 relates the bacterial
count of log-phase harvested inoculum to the day-1 bacillary implantation in rabbit
lungs. Our data indicate that it is likely that repetitive-exposure rabbits were infected
on every occasion of exposure as bacteria were recovered from the lungs of all rabbits
in the lowest optical-density exposure group of our chamber titration experiment (Fig
2.2).
y = 9418(x) − 27.24 (2.1)
Slope 95% confidence: 8014-10823
Y-intercept 95% confidence: -842.3 - 787.8
R2: 0.9999
y = 9352(x) − 34.06 (2.2)
Slope 95% confidence: 9163 - 9541
Y-intercept 95% confidence: -75.81 - 143.9
R2: 1.000
y = 0.0007037(x) − 250.0 (2.3)
Slope 95% confidence: 0.0004879 - 0.0009195
Y-intercept 95% confidence: -2020 - 1520
R2: 0.9139
We monitored rabbits using computer tomography (CT) scans. These data
showed that 75% (3 of 4) of the animals in the repetitive exposure group experienced
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Madison Chamber standard curve
Figure 2.2: Titration of bacterial concentration in aerosol inoculum mapping optical density of
aerosol inoculum to day-1 CFU recovered from rabbit lungs. (A) Experimental outline. (B) Bacteria
recovered from rabbit lungs reported by optical density group and by dilution set. Three rabbits were
used for each optical density group. (C) Optical density mapped to CFU counts using 10x dilution
in the OD 0.1 and 1.0 range, and neat (undiluted) counts in the OD 0.01 range. (D) Optical density
mapped to CFU counts using 10x dilution in the OD 0.1 and 1.0 range. Counts in the 0.01 group
were adjusted for tissue-homogenates CFU signal depression by multiplying OD 0.01 data-points by
the ratio of average signal depression between 10x and neat dilutions in the OD 1.0 group, shown in
S1B. (E-F) Best-fit linear regression models based on the averages of data-points in each OD group
in C and D. All equations are calculated for the best-fit line between data-points.
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at-least one cavity versus 25% (1 of 4) of the animals in the repetitive exposure group
(Fig 2.1B). Of those animals that developed cavities, those in the repetitive exposure
group showed a trend toward more cavities per animal than those in the single ex-
posure group (Fig 2.1C). On week-10 of the experiment, the rabbits were sacrificed
and the lungs were fixed. Semi-quantitative gross pathologic analysis showed that
rabbits in the repetitive aerosol group experienced worse lung disease than those in
the single exposure group (Fig 2.1D and Fig 2.3). In light of the limited number of
rabbits involved in this study, these data suggest that repetitive exposure caused an
increase in the severity of disease as well as the frequency and severity of cavities.
2.2.2 Cavities from repetitive exposure formed quickly, showed
dynamic behavior, and often persisted for many weeks
Focal matrix depletion precedes tuberculosis cavitation, so we sought to define the
optimal treatment window for the prevention of cavitation as the weeks before the
greatest frequency of cavitation. To study the dynamics of cavity formation gener-
ated by repetitive exposure to M. tb, we infected eight rabbits using the repetitive
exposure protocol and observed their lungs using CT scans at weeks three, six, eight
and 16. The overall frequency of cavitation in this study was 87% (7 of 8), further
supporting our previous observations with the repetitive exposure method (Fig 2.4A).
The greatest increase in the frequency of cavitation occurred between weeks 6 and 8,
during which time the frequency of cavitation among rabbits increased from 11% (1
of 8) at week six to 50% (4 of 8) at week 8 (Fig 2.4A). Between week 8 and week 16,
the frequency of cavitation increased modestly to 63% (5 of 8) but was marked by
occasional resolution of existing cavities and the generation of new cavities.
Cavity morphology over time was observed by CT scan reconstructions. We
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Comparison of fixed lungs from the single and repetitive exposure group
rabbits
Figure 2.3: Gross images of formalin fixed lungs showing the dorsal aspect of the lungs. (A) Lungs
from rabbits in the single exposure group. (B) Lungs from rabbits in the repetitive exposure group.
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Patterns of cavity growth and shrink in rabbits infected by repetitive
aerosol exposure
Figure 2.4: Timing of cavitation and cavity growth dynamics in the repetitive aerosol method.
(A) The frequency of cavitation mapped to time after start of infection. The solid line indicates
the cumulative frequency of cavitation among the cohort of 8 rabbits. The dashed line indicates
the frequency of cavitation among the cohort at the specific time point and is distinguished from
the solid line by the occurrence of cavity resolution. (B) Cavity volume mapped to time after the
start of infection for four representative cavities demonstrating (1) continuous growth, (2, 3) growth
and shrinking behavior, and (4) growth and resolution. Cavities were identified as lung volumes
not connected to the normal bronchial structure with densities between -875 and -1024 Hounsfield
units and points on the x-axis indicating a non-cavitary focus are plotted at the limit-of-resolution
for the CT scanner. The y-axis is plotted using a logarithmic base 3 scale since measured volume
varies closely as the cube of the radius of a spheroid object so that relationship among cavity
volumes are more comparable to the two-dimensional reconstructions in C. (C) Transverse CT-scan
reconstructions showing each of the foci identified in B.
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used density segmentation analysis to identify cavities as air-filled spaces that were
not connected to the bronchial tree. From this analysis, we identified three patterns
of change in cavity morphology: (1) cavity growth (Fig 2.4B and C, example 1)
(2) cavity shrinkage (Fig 2.4B and C, example 2 and 3), and (3) cavity resolution
(Fig 2.4B and C, example 4). Together, these data demonstrate that cavities most-
often formed between six and eight weeks after the initial aerosol exposure and were
persistent though dynamic structures between weeks eight and 16 of the study.
2.2.3 The size of the pre-cavity consolidated focus does not
impose a boundary on final cavity size
One potential hypothesis to explain the dynamic behavior of tuberculosis cavities
proposes that the maximum size of a cavity is determined by the boundaries of the
pre-cavity consolidated focus. If this hypothesis is true, then a conceptual model for
tuberculosis cavitation should be straightforward and is comprised of the following
steps:
1. Granuloma formation
2. Central matrix depletion and necrosis
3. Erosion of necrotic debris through a bronchus
We conducted a thorough study of the dynamics of cavity formation, growth
and resolution using CT-scans generated from serial time-points (Fig 2.5). In this
study, we considered the total lesion volume (Vlesion) as the volume of the cavity
(Vcavity) plus the volume of consolidation around the cavity (Vconsolidation). We then
identified the full set of cavities generated during our repetitive aerosol exposure pilot
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studies and plotted Vlesion for each of the serial CT time-points at weeks three, six,
eight, and 16 following the start of the experiment (Fig 2.5A).
Approximately 50% of the cavities observed in this study were the largest
at the initial time of observation and shrank by some degree in serial CT scans.
About 25% of the cavities grew steadily over serial CT scans. About 20% of the
cavities displayed dynamic growing the shrinking behavior. Finally, a minority of the
cavities (4%) underwent complete resolution and were not radiologically apparent
at the final CT-scan (Fig 2.5B and C). These findings suggest that cavity volume
changes over time and can grow and shrink. Importantly, many of the cavities that
demonstrated growing behavior showed Vlesion changes that grew by more than 2-
times their initial volume, suggesting that the volume of a pre-existing consolidated
focus, or pre-existing cavity, does not impose a boundary on the final cavity size.
Next, we asked whether the size of the initial consolidated focus limits the
absolute size of the cavitary lesion (Vlesion). We used serial CT scans taken at week
6 and later. We identified all instances of consolidated foci and new cavities in each
of these scans. Next, we identified the preexisting consolidated focus in the CT-
scan taken from the imaging time-point immediately preceding the scan where the
lesion was identified. Common anatomical landmarks were used to identify the most-
probably precursor consolidated focus. Finally, we reported the ratio of Vlesion to the
size of the preexisting consolidated focus (Vlesion, t-1) (Fig 2.5D and E).
These data demonstrate that cavitation is often accompanied by a rapid (two-
weeks or less) expansion event. Most ratios for solid lesions, foci that did not cavitate,
remain close to 1.0. However, cavitation was accompanied by an average 1.87 times
expansion in the size of the lesion (range: 0.67 9.30) (Fig 2.5E).
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Dynamics of cavity growth and shrink over time
Figure 2.5: A study of the frequency of cavity growth and shrink over time in rabbits infected
by repetitive aerosol exposure. (A) Study schematic showing the relationship between study week,
CT-scan times T1, T2 and T3, and volumes Vlesion and Vlesion, t-1. The volume Vlesion is always
the area of consolidation + the area of cavity-space if a cavity exists. (B) The fraction of all
cavities identified that demonstrated each behavior. (C) Plots displaying Vlesion at each time-point.
(D) An example transverse plane CT-scan reconstruction showing demonstrating cavitation from a
consolidated focus. Scans were taken two-weeks apart. (E) The relative growth in lesion volume for
consolidated foci that did not cavitate compared with those that did cavitate.
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2.2.4 A bubble-like morphology occurs in more than 50% of
cavities generated by repeated exposure
We spatially co-registered terminal CT-scans with high-resolution photographs of
fixed lung-tissue. This technique allowed us to validate that cavities observed follow-
ing histologic preparation were not artifacts of tissue sectioning, but rather cavities
in situ. Dr. Elizabeth Ihms reviewed the histologic morphology of each lesion and
inferred four distinct morphological sub-types (Fig 2.6). The category “smooth” or
“bubble-like” accounted for 50% of all cavity-types (Fig 2.6A).
2.2.5 Histologic observations support the hypothesis that cen-
tral necrosis and matrix depletion are prerequisites for
cavitation
A large body of historic literature, in addition to our own observations, suggests
that tuberculosis cavities arise from necrotic granulomas. Since we had not previ-
ously worked with a model that generates cavities by repetitive exposure to M. tb,
we investigated whether the pathologic phenotype of lung destruction was similar to
human disease. Histology samples collected from rabbits infected by repetitive expo-
sure displayed many of the microscopic findings described in tuberculosis pathology
reports (Fig 2.7)4,14,132,135. These hallmarks included granulomas, necrotic granulo-
mas and cavities. Histologic observations from the repetitive exposure model show
that the cytoarchitecture between necrotic granulomas and cavities was similar, fur-
ther supporting a close relationship between the two lesions (Fig 2.7A and B, and Fig
2.8).
The cavities generated by repetitive exposure were marked by large prolifera-
tions of acid-fast bacteria along their inner surface and a wall enriched with fibrosis
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The four microscopic morphologies of rabbit cavities
Figure 2.6: A study of the microscopic morphologies of rabbit cavities generated by repetitive
aerosol exposure based on 49 cavities. (A) Frequency of each morphologic type. (B) Representative
H&E section of a cavity showing “smooth” or “bubble-like” morphology. (C) Representative H&E
section of a cavity showing “rough” morphology. (D) Representative H&E section of a cavity showing
“mixed” morphology. (E) Representative H&E section of a cavity showing “fibrous” morphology.
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Histopathology of the cavity wall in the rabbit model
Figure 2.7: Histologic patterns of tuberculosis lesions in rabbits infected by repetitive aerosol
exposure. (A) Representative H&E demonstrating lesions commonly observed in rabbits infected
by repetitive aerosol exposure. (B) Serial sections from the boxed region demarcated in A stained
with H&E, acid-fast bacilli, and Masson’s trichrome stain. Masson’s trichrome identifies collagen in
blue hues. (C) Overview of the model for collagenase mediated destruction of extracellular matrix
in proximity to a cavity.
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(Fig 2.7B and Fig 2.8C). Since our investigations are predicated on the pathologic
observation that matrix depletion predisposes to cavitation, we also confirmed that
collagen matrix depletion was a hallmark of cavitary lesions from repetitive exposure
(Fig 2.8). These observations show that repetitive aerosol exposure in rabbits gen-
erates a spectrum of histologic lesions commonly observed in tuberculosis pathology
studies and validates the model for our studies by showing that pathologic matrix
depletion is modeled by rabbits following repetitive aerosol infection.
2.3 Discussion
We have developed a novel model for cavitary tuberculosis based on repetitive aerosol
exposure to virulent M. tb. Our data show that repetitive exposure over a two week
period produced more advanced disease and more cavities than a single exposure,
even when we carefully adjusted the concentrations bacteria in the aerosol inoculum
to provide the same total exposure between groups. More generally, our findings pro-
vide experimental evidence that the pattern of exposure is a variable in determining
the pattern of tuberculosis. Specifically, this finding suggests a link between repetitive
exposure and tuberculosis exacerbation and is further supported by recent epidemi-
ological evidence that multiple exposures to infected contacts increases the risk of
tuberculosis progression134,136. An association between repetitive exposure and se-
vere tuberculosis may have important implications for epidemiology and infection
control in high-incidence regions of the world.
Our experiments did not evaluate the mechanism of repetitive-exposure related
disease exacerbation; however, it is possible that the driver of more severe disease in
repeatedly exposed animals is repeated priming of cell-mediated immunity. Although
untested, repetitive exposure may cause a cascading set of T-cell priming and expan-
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Collagen-matrix depletion at the cavity wall
Figure 2.8: Collagen enrichment in lung lesions from rabbits infected with M. tb. (A) Examples of
H&E stained tissue fields used for quantification of collagen enrichment analysis. Black rectangles
represent example high-resolution fields used for quantification in B and traces in C. Arrow-heads
indicate examples of the histologic regions surveyed during the relative collagen quantification re-
ported in B. (B) Relative enrichment in collagen identified by blue hues in the Masson’s trichrome
stain. Surveys of collagen enrichment were random in normal appearing lung tissue and from regions
500 µm in length at the centers of lesion fields in granulomas and necrotic granulomas. Surveys of
collagen enrichment from the cavity edge were defined as regions within 150 µm of the cavity edge.
Multiple surveys were taken from non-overlapping areas within each region and the number above
each category indicates the number of unique lesions surveyed. (C) Relative tissue density (grey
line, right y-axis) and collagen density (black line, left y-axis) along linear traces crossing two gran-
ulomas, two necrotic granulomas, and two cavities. All traces are set to the same x and y scale and
the minor hash marks in the lowest plot show the regular pattern of surveys continued along each
lesion. Dotted lines indicate cavity space on histology.
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sion events that disproportionately exacerbate the immune response against M. tb
antigen in the lung137.
Our data show that modeling cavitary tuberculosis by repetitive aerosol ex-
posure also models a spectrum of human lesions and pathologic matrix depletion
associated with caseous and cavitary pulmonary tuberculosis138.
Our results demonstrate an entirely new system to study tuberculosis cavities.
We show that repetitive exposure to aerosolized M. tb produces a pathologically rele-
vant phenotype for screening pre-clinical agents toward the prevention and treatment
of cavity formation.
2.3.1 Interpretations of dynamic cavity growth and shrink
behavior
The dynamic growth and shrink behavior of cavities supports the conclusion that the
size of the pre-cavitary consolidated focus is not a limit for the maximum size of the
cavity derived from the pre-cavitary focus. Instead, cavities appear to have dynamic
behavior over time and can grow, shrink, or resolve. One possible explanation for
this dynamic behavior is the movement of caseum into and out of the cavity via
the draining bronchus. However, this explanation only accounts for the dynamic
size of the cavity-wall, but does not explain the ability of the entire cavitary focus
(cavity-space and surrounding consolidation) to grow so that the new boundaries of
the cavity-space exceed the original out-boundaries of consolidation. Therefore, it
is likely that one or more physical or biochemical mechanisms drives large cavity
expansion.
Our analysis of the ratio of cavity-lesion size (Vlesion) to the size of the pre-
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cavitary focus compared to the same metric for lesions that did not cavitate provides
another interesting insight into the cavitation event. In this comparison, cavitation
was often accompanied by a sharp increase in overall lesion volume that was not ob-
served in lesions that failed to cavitate. We argue that this is evidence for a stretching
effect on the cavity wall. As central necrosis and matrix breakdown drive cavitation,
the mechanical cross-sectional support within the lesion is reduced. As a result, the
inspiration induced tension exhibited in all directions by alveoli stretches the cavity
wall. The cavity wall is eventually balanced with the pull of alveoli by tangentially-
vectored tension enforced by the fibrotic wall of the cavity. This explanation remains
unsubstantiated, but the apices of the lungs are the sites of the greatest mechanical
stress and we suggest that a tension-driven-expansion explanation may help explain
why large cavities tend to occur in the apices of the lungs.
Another possible mechanism for cavity growth is continual necrosis and matrix-
breakdown at the periphery of the cavity accompanied by further sloughing of new
necrotic debris. This would have the effect of growing the overall size of the cavity-
space beyond the boundaries of the pre-cavitary focus. Our studies provide insuffi-
cient evidence to rule out either tension-driven-expansion or peripheral remodeling
as the major driver of large cavity expansion. Likewise, it is also possible that both
mechanisms play a role in cavity expansion.
2.3.2 A positive-pressure model may explain the high-prevalence
of cavities with a bubble-like morphology
Greater than 50% of the cavities observed following repeated aerosol exposure con-
tained a “smooth” or “bubble-like” morphology. In her analysis, Dr. Elizabeth
Ihms also noted that these cavities were, on average, younger than cavities show-
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ing other morphologies. Corroborating our observations in the repetitive aerosol
rabbit model, Ordonez et al., also observed a similar “bubble-like” morphology in
C3HeB/FeJ mice139. Several reports from tuberculosis pathology studies also noted
the presence of a “bubble-like” cavity morphology. Therefore, we suggest a positive-
pressure model best explains these observations. In this hypothesis, a necrotic gran-
uloma connects to a bronchus and a small amount of necrotic debris occludes the
draining bronchus. Respiratory inspiration pulls the walls of the cavity apart and
creates a vacuum within the micro-cavity. The vacuum pulls small amounts of air
into the cavity to create positive pressure when the respiratory muscles relax. This
pattern of events may explain the earliest event in cavitation but this model requires
further investigation. Finally, it is also possible that the bubble-like morphology is
an artifact of both the rabbit and C3HeB/FeJ cavity models.
2.3.3 Limitations of the repetitive aerosol exposure model
There are several important limitations for the rabbit cavity model based on repetitive
aerosol exposure. These limitations are important because they define the range of
appropriate experimental applications for the repetitive aerosol exposure model.
First, the high rate of cavitation is artificial. Estimates for the frequency of
cavitation among cases of active tuberculosis vary from 10 — 50%. In Chapter 1 we
report a frequency of 15%. In contrast, the repetitive aerosol model develops cavities
at a frequency between 60 — 80%. Therefore, the repetitive exposure model may not
be appropriate for experiments where the frequency of cavitation is expected to be
similar to the frequency observed in human tuberculosis.
Second, it is difficult to define the repetitive exposure model as a model of
primary or post-primary tuberculosis. Post-primary tuberculosis is defined as tuber-
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culosis in the context of a pre-existing adaptive-immune response. This distinction is
not trivial since pathology studies demonstrate distinct patterns of disease for primary
and post-primary tuberculosis. In the repetitive exposure model rabbits are näıve to
tuberculosis antigen at the time of the first aerosol exposure. However, rabbits were
shown to have acquired an adaptive-immune response to tuberculosis antigen by the
end of the two-week exposure period (Fig 2.9A and B). Therefore, the first of five
repetitive exposures may be considered a primary exposure event, but many of the
disease foci probably develop in the context of an adaptive-immune response to M.
tb antigen.
Finally, cavitation in the repetitive aerosol model occurs without polarized
lung-lobe distribution (Fig 2.9C). Pathology studies describe post-primary disease
foci predominately occurring in the apical lobes. Our studies show that the repetitive
aerosol exposure model develops cavities distributed evenly through all lung lobes of
the rabbit. The repetitive aerosol exposure model may not be appropriate for in-
vestigating hypotheses concerning the pathogenesis of apically-oriented post-primary
disease.
These limitations aside, the high rate of cavitation seen in this model is ad-
vantageous for studies where cavities are analyzed as discrete biological occurrences.
For our studies, the development of the repetitive exposure model enabled efficient
screening for in vivo inhibitors of cavitation. These inhibition studies are the subjects
of Chapters 3 and 4 of this manuscript.
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Mantoux test results and the distribution of disease by lobe in rabbit
lungs
Figure 2.9: Mantoux test results and the distribution of disease by lobe in rabbit lungs. (A) An
example of a negative PPD-reaction and a positive PPD-reaction in the rabbit model. The equation
for calculating induration size is shown. The average diameter of the induration is measures as two
perpendicular lengths taken across the injection site bounded by the start of the thickened region
of skin. The thickness of the induration is calculated by caliper as the minimum thickenss of skin
that can be pinched and held. (B) PPD-responses at the end of the two-week repetitive aerosol
infection period compared with antigen-experienced controls and M. tb-antigen näıve rabbits. (C)
The distribution of disease between lobes of rabbit lungs.
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Chapter 3
Pharmacologic inhibition of the
collagenase matrix
metalloproteinases during cavity
formation in the rabbit model
Michael E. Urbanowski · Elizabeth A. Ihms · Kristina Bigelow · André
Kübler · Paul T. Elkington · William R. Bishai
“A cloud fell down from the heavens,
And broke on the mountains brow;
It scattered the dusky fragments
All over the vale below.
The moon and the stars were anxious
To know what its fate might be;
So they rushed to the azure op’ning,
And all peered down to see.”
A Starry Night
by Paul Lawrence Dunbar.
Widely regarded as one of the greatest poets
and writers in 1900, died of tuberculosis in 1906
at the age of 33.
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3.1 Introduction
In the previous chapter we describe a novel rabbit model for cavitary tuberculosis
based on repetitive aerosol exposure. This model reliably generates multiple cavi-
tary foci in 60 — 80% of study animals in a short period of time. Compared with
single exposures of the same total bacterial burden, repetitive exposure generated
more advanced disease and more cavitary foci, suggesting that repetitive exposure to
aerosolized bacilli may be an important determinant for the severity of tuberculosis
in high-incidence settings. We also confirmed that this model develops human-like
tuberculosis cavities where matrix depletion was a pathologic feature of cavity de-
velopment. Based on these observations, we endorse the repetitive aerosol exposure
model as an advantageous tool for studying cavitation.
The collagenase MMPs and cathepsin K are the two lead candidates for molec-
ular mediators of tissue matrix destruction in tuberculosis identified by Kübler et
al91,131. In this chapter, we apply the repetitive aerosol exposure model to screen
cipemastat, a potent inhibitor of the collagenase matrix metalloproteinases (MMPs),
as a targeted inhibitor and therapeutic agent to limit tuberculosis cavitation140,141.
3.1.1 The biology of matrix metalloproteinases
The MMPs are a group of 23 homologous metalloproteinases that are unified by the
need for zinc binding within their active-sites and their ability to act as extracellular
endopeptidases142. MMPs act as critical mediators over cell-cell interactions, over
cell-extracellular matrix interactions, and over interactions between cells and soluble
factors. The MMP family proteins were originally recognized for their proteolytic
activity against collagenous substrates in tadpoles143. More formally, the MMPs are
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defined as a subfamily of the zinc metalloprotease family M10 with distinct activ-
ities against extracellular and cell-surface associated targets142. A closely related
group of proteins are the disintegrin and metalloprotease (ADAMs) which localize to
the mammalian cell membrane and function both as sheddases that cleaving other
membrane-targeted substrates and as mediators over cell-cell interactions144.
Substrate specificities distinguish the 23 MMP isoforms. The original MMPs
were noted for their collagenase activity. In humans, the canonical collagenases are
MMP-1, 8 and 13, while the human MMP gelatinases are MMP-2 and MMP-9. Ad-
ditional substrate groups include the stromelysins (MMP-3, MMP-10, MMP-11), the
matrilysins (MMP-7 and MMP-26). Although these groups help distinguish the
MMPs, there is often overlap in the substrate profile, even between group mem-
bers145. Expression of functional MMPs is highly regulated based on tissue type and
physiological context. Therefore, it is now recognized that the MMPs are part of a
complex cellular toolbox of extracellular proteases with diverse, though specific, bio-
logical functions142. For instance, MMP-1 (a collagenase) is further characterized to
cleave type I collagen and fibronectin (allowing cell migration), IGFBP-3 (to increase
the bioavailability of IGF1), participate in the processing of IL-1 (to dampen inflam-
mation), and PAR1 (activation of PAR1)146,147. Likewise, MMP-9 (a gelatinase) is
further characterized to cleave plasminogen, IL-1 (similar to MMP-1, to dampen in-
flammation), IL-2R (to reduce inflammation), precursor TGF, and collagen IV (to
induce thymic neovascularization)148.
Super-cellular localization and domain composition are also used to group
the MMPs145,149. All MMPs contain a conserved signal-peptide domain, propeptide
domain, and zinc-coordinating catalytic domains responsible for endopeptidase activ-
ity. The MMPs 1, 3, 8, 10, 12, 13, 19, 20 and 27 contain an additional hemopexin
domain that confers substrate specificity, mediates pro-peptide activation, and me-
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diates TIMP-mediated inactivation. The specific functions and substrate specificity
conferred by the hemopexin domain very among individual MMPs. The gelatinase
MMPs 2 and 9 contain both a hemopexin domain and a set of three repeated type-II
fibronectin domains located within the catalytic domain. The fibronectin domains
mediate extracellular binding with gelatin, collagen, and laminins. The MMPs-14,
15, 16, 17 24, and 25 contain a transmembrane domain (MMP-14, 15, 16, 24) or a
GPI anchor domain (MMP-17 and 25) and together are referred to as the membrane-
type MMPs. Most membrane-type MMPs are capable of activating pro-MMP2 and
degrading collagen.
The expression and activity of MMPs are highly regulated150. At a tissue-level,
transcription factors, especially AP-1, NFAT, and NF-κB regulate the expression of
MMPs151. A few studies also suggest that epigenetic modifications to DNA control
the accessibility of MMP genes to transcriptional machinery, though most MMPs
cluster together in a small region of chromosome 11 in the absence of CpG islands152.
Furthermore, all MMPs are translated as propeptides with a propeptide domain at
their N-terminal end which covers the catalytic site of the catalytic domain. Pro-
teolytic cleavage of the N-terminal propeptide domain is required before MMPs can
become active153 and is mediated by the action of serine proteases such as plasmin154.
A special, though important, case of propeptide cleavage and activation is the acti-
vation of MMP-9 by MMP-3155. Therefore, MMPs can also act as activators of other
MMPs156,157.
MMP activity is also regulated by proteins called tissue inhibitors of metal-
loproteinases (TIMPs)96,158. TIMPs are produced and released by mammalian cells
and are highly conserved among mammalian lineages. There are four TIMP genes in
humans. In general, TIMP-2 and TIMP-3 are capable of inhibiting all MMPs and
many ADAMs while TIMP-1 and TIMP-4 are more specific for various members of
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the MMP and ADAM families. The TIMPs provide an additional level of spatial
regulation over the extracellular MMPs so the ratio of MMP to TIMP concentration
is a determinant over MMP activity.
The MMPs also have diverse physiological roles and MMP biology is still a
very active area of research. Here highlighted are three well-described physiological
roles for MMPs.
1. Embryogenesis: MMPs were first described in the context of tadpole de-
velopment143 and subsequent studies showed that MMPs were dramatically up-
regulated during embryogenesis in humans and mouse models159,160 . Therefore,
MMPs play a critical role in tissue pattern formation and morphogenesis and
are primary agents in extracellular matrix remodeling.
2. Cell migration: MMPs are critical for the movement of cells through tissues of
the body161,162. One example is the movement of immune cells through tissues
to the site of an infection. These immune cells secrete soluble MMPs and
transmembrane-domain containing MMPs at the leading edge of cell migration
to facilitate matrix breakdown ahead of the migration path163–166.
3. Immune modulation: A growing body of literature describes the immune-
modulating effects of MMPs167 . In these studies, immune modulation is achieved
by a combination of substrate specificity and regulation over MMP activity. The
best-describe example of MMP-immune modulation is the cleavage of members
of the TNF superfamily by ADAM17 and MMP-8168–170.
In additional to the physiological roles identified for MMPs, MMPs are also
implicated in disease171. Again, here highlighted are three examples of the roles that
MMPs play in the pathophysiology of disease.
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1. Cancer metastasis: MMPs are implicated in cancer tissue invasion and metas-
tasis152,172. Cancer cells express MMPs during primary tumor cell invasion, to
move through the endothelial barrier of blood vessels and into tissues during
metastasis, and to promote angiogenesis.
2. Autoimmune arthritis: The collagenase MMPs-1 and 13 may mediate au-
toimmune arthritis173. An imbalance of the MMP-TIMP ratio at joints is driven
by increased TNFα signaling to cause joint damage.
3. Multiple sclerosis: MMP protein concentration is increased in the CSF of
patients with multiple sclerosis and in the brains of animals modeling multiple
sclerosis174. Furthermore, experimental treatment with MMP inhibitors in mod-
els of multiple sclerosis reduced the extent of brain damage. The mechanism of
MMPs influence on multiple sclerosis pathology is less clear and may involve a
combination of immune modulation and enhanced penetration of immune cells
through the blood brain barrier.
3.1.2 A role for MMPs in tuberculosis
Several studies implicate MMPs as a biochemical drivers of cavitation. Transcrip-
tion analysis of sputum and bronchoalveolar lavage samples from patients with active
tuberculosis show the increased presence of MMP transcripts compared to samples
from individuals without active tuberculosis87–89. These observations were further
supported by experiments in model systems. Volkman et al. demonstrated that the
zebrafish homologue of human gelatinase MMP-9 helped mediate granuloma forma-
tion90 and Ordonez et al., visualized MMP-9 using ex vivo optical imaging in mouse
lungs139. Finally, Elkington and Friedland have extensively investigated and discussed
the pathophysiological niche for MMPs in tuberculosis78,86,89,103,175.
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Kübler and colleagues worked in a rabbit model and confirmed that MMP-1
expression was spatially organized with regions of tuberculosis lung disease. Their
work also establishes the validity of the rabbit model in studies to address the prote-
olytic basis of cavitation. Kübler et al. performed RNA-seq on tissue collected from
rabbits modeling cavitary disease and showed that MMP-1 transcripts increased in
diseased lungs91. Elegantly, Kübler et al. also took advantage of the spatial sepa-
ration between lesions enabled by the size of the rabbit lungs91. The investigators
collected tissue from regions with varying proximity to the cavity wall and showed
that there was spatial specificity to MMP-1 expression. Regions closer to the cav-
ity wall expressed more MMP-1. These results demonstrate that MMP-1 transcripts
accumulate in the areas near M. tb-induced lung damage suggesting that MMP-1
activity might drive tissue destruction in tuberculosis131. We hypothesized that if
MMP-1 was the major driver of tissue matrix destruction in tuberculosis patients,
then inhibiting MMP-1 should prevent cavities (Fig 2.7C).
3.1.3 Cipemastat: a potent and selective inhibitor of the col-
lagenase MMPs
We undertook a literature search for selective inhibitors of MMPs and obtained
Cipemastat (Ro 32-3555, trade name Trocade), a potent inhibitor of MMP-1. The
drug was originally developed by the Roche Corporation as an anti-arthritis agent
but discontinued in the 2000s140,141. The use of cipemastat for our studies is advan-
tageous several reasons. It was shown to inhibit MMP-mediated tissue destruction
during in vitro assays, in mammalian model systems, and in humans. Cipemastat is
also highly specific for the collagenase MMPs 1, 8 and 13 with IC50 values between
3 and 4 nanomolar. By comparison, the IC50 values for non-collagenase MMP-3 (a
stromelysin) and MMP-2 (a gelatinase) are 527 nanomolar and 154 nanomolar re-
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spectively. Finally, cipemastat also had good pharmacokinetic profile in mammalian
models. The Tmax in rats is reported as 0.05 hours, a half-life of 3.8 hours, and a
Cmax of 1,492 ng/mL following single oral dose of 25 mg/kg in rats
141.
3.2 Results
3.2.1 The collagenase MMP-inhibitor cipemastat is orally
bioavailable in rabbits and reaches therapeutic concen-
trations in the peripheral blood
We first confirmed that cipemastat did not have intrinsic anti-mycobacterial prop-
erties but was able to inhibit MMP-1 in vitro (Table 3.1 and Fig 3.1). Next, we
conducted a pharmacokinetic study to confirm that cipemastat was orally bioavail-
able in rabbits and had suitable kinetics for a daily dosing regimen (Table 3.2). During
the PK study, 3 rabbits were given a single oral dose of cipemastat at a concentration
of 100 mg/kg of body weight, a dose that was shown to be within the tolerability and
efficacy range in humans and animal studies176,177.
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Table 3.1: Results of anti-mycobacterial activity testing for cipemastat
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In vitro inhibition of MMP-1 by cipemastat
Figure 3.1: Coomassie blue stained gel electrophoresis of collagen incubated in the presence of
human MMP-1, Trocade + MMP-1, and Troacade + MMP-1 in PediaSure vehicle.
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The results of the PK study showed a 24-hour AUC0-24 hours of 21.79 h·µg/mL
(49.9 µM·h), consistent with previouly published oral dosing studies (Table 1)176,177
(Table 3.2 and Fig 3.2). Importantly, we found that the plasma concentration re-
mained above the published IC50 of cipemastat for MMP-1 at 26 ng/mL (60 nM) for
22 out of 24 hours following a single oral dose141. These results suggest that cipemas-
tat shows good oral bioavaliability in rabbits and confirms that a daily dosing regimen
is sufficient to maintain plasma concentration levels above the IC50 during most of a
24 hour period.
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PK curve for cipemastat in rabbit plasma
Figure 3.2: Plasma concentration curves of cipemastat in rabbit plasma following a single oral 100
mg/kg dose. (A) Graph showing traces for individual rabbits in the PK study. (B) Graph showing
a curve representing the arithmetic means with standard-error bars of PK curves from the three













































































































































































































3.2.2 Cipemastat monotherapy did not protect against ex-
tensive lung destruction and cavitation
We randomized 18 rabbits into an vehicle group (n=8) and a cipemastat group
(n=10). All rabbits received 1 mL of PediaSure per kilogram of body weight. Rab-
bits in the cipemastat group received 100 mg/kg of cipemastat in PediaSure, the
same dosed that was validated during our PK study. Cipemastat was given orally
from study weeks 5 through 10. This treatment window was consistent with the five
weeks preceding the maximum frequency of cavitation and the time during which we
predict that pathologic lesions will undergo matrix depletion (Fig 3.3). Two rabbits
were excluded from our analysis due to poor adherence to oral dosing. One rabbit was
excluded from the cipemastat group and one rabbit was excluded from the vehicle
group. Our results are based on 7 control group rabbits and 9 cipemastat treated
rabbits.
During weeks 7, 9, 12 and 14 we performed breath-hold computerized tomog-
raphy (CT) scans on all study rabbits. These CT scans revealed no difference in
the number of cavities or severity of cavitation between the control and treatment
groups throughout the study (Fig 3.4 and Fig 3.5A, 6B). We did notice a repeated
trend toward worse cavitary disease among rabbits in the cipemastat-treated group.
The animals were sacrificed during week 14 and the lungs were fixed and scored for
disease severity by two independent blinded observers (Fig 3.5C). We also quantified
the extent of disease within the lungs by cutting the lungs in serial sections in the
transverse plane and reporting the overall percentage of all lung slices with grossly
visible disease (Fig 3.5C). Neither severity scoring nor disease quantification showed
a difference between experimental groups.
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3.2.3 Collagen content at cavity walls was not changed by
cipemastat treatment
Tuberculosis lung lesions are often encircled by a fibrotic wall132. This pathologic ma-
trix deposition is also a feature of rabbits modeling cavitary tuberculosis (Fig 2.7B and
Fig 3.5D). Since cipemastat inhibits collagenase activity, we predicted that cipema-
stat administration should increase the collagen content around tuberculosis lesions.
We used hue-thresholding to quantify the amount of collagen identified in blue by
applying Masson’s trichrome stain to formalin-fixed parafin-embedded lung sections
of cavities (Fig 3.5D). Using this method we were unable to identify any difference
in the collagenous content of cavity walls suggesting that cipemastat treatment did
not change the phenotype of pathologic collagen accumulation around cavities in the
rabbit model (Fig 3.5D).
3.3 Discussion
We took advantage of the repetitive aerosol exposure model to screen cipemistat, a
potent and specific MMP-1 inhibitor, as an inhibitor of cavitation141. Our study was
supported by a molecular phenotype in which MMP-1 expression increased around
tuberculous lesions with central matrix destruction131. In these experiments, we ad-
ministered cipemistat for four weeks preceding the development of caseous and cav-
itary lesions in the repetitive aerosol model. However, our results did not show a
reduction in cavitation or disease severity.
As part of our investigations, we confirmed that the plasma concentrations of
cipemistat were well above the IC50 during the 24 hour dosing cycle. We did not
sample the concentration of cipemistat in tuberculosis lesions, therefore it is possible
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that cipemistat did not reach inhibitory concentrations within granulomas undergoing
matrix destruction. Furthermore, MMP activity may be highly localized in pericellu-
lar niches178. Alternatively, MMP-1 may act in conjunction with other extracellular
collagenases to drive matrix depletion and that the inactivation of MMP-1 did not
appreciably change the dynamics of cavity formation, reflecting redundancy in the
proteolytic cascade. Finally, it is possible that MMP-1 is not a mediator of matrix
depletion and cavitation. The increased expression of MMP-1 at tuberculosis lesions
may be purely associative or indicate another role for MMP-1 in the pathobiology of
tuberculosis.
3.3.1 Reconsidering the role of MMPs in tuberculosis lung
pathology
The results presented in this chapter show that cipemastat monotherapy of 100 mg/kg
by body-weight was unable to protect against cavitation in a rabbit model of cavitary
tuberculosis. It is possible that MMPs are not the primary mediators of extracellular
matrix destruction. Conversely, the introduction highlights a large body of literature
supporting a role for MMPs in tuberculosis89,90,103,131. Recent investigations high-
light MMPs as immune-modulators by acting as extracellular cytokine sheddases167.
Therefore, it is possible that MMPs act as mediators over the immune response to
tuberculosis rather than at the final step in matrix breakdown. One attractive hy-
pothesis concerns the circular effects of MMP activation and TNFα production. MMP
expression is driven by inflammatory cytokines including TNFα, but MMPs also show
proteolytic specificity for pro-protein members of the TNFα family of inflammatory
molecules. It is possible that MMP activity in tuberculous lesions is responsible for
TNFα activation. A roll for MMPs as the primary mediators of TNFα activation may
help explain our observation that cipemastat treatment was associated with a trend
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toward worse disease and cavitation during our rabbit study. Further investigations
are needed to clarify the contributions and redundancies of individual MMPs to lung
inflammation in tuberculosis179.
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Experimental overview for cipemastat study in rabbits
Figure 3.3: Experimental overview to investigate the pharmacologic inhibition of tissue destruction
and cavitation using cipemastat in rabbits infected with M. tb.
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Comparison of fixed lungs from control rabbits and rabbits treated with
cipemastat
Figure 3.4: Comparison of fixed lungs from control rabbits and rabbits treated with cipemastat.
Gross images of formalin fixed lungs showing the dorsal aspect of the lungs. (A) Lungs from rabbits
in the vehicle treated group. (B) Lungs from rabbits in the cipemastat treated group.
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Disease severity and cavitation in cipemastat treated rabbits compared
with controls
Figure 3.5: The extent of disease severity and cavitation in cipemastat treated rabbits compared
with controls. (A) Average number of cavities per animal for weeks 7, 9, 12 and 14. (B) Average
volume of the lung identified as cavity volume by CT-scan and segmentation analysis for weeks 7,
9, 12 and 14. (C) Disease severity scores of lungs assigned subjectively by two independent blinded
observers and quantified as the fraction of lung identified as disease in transversely splayed lungs.
(D) Quantification of collagen accumulation at the walls of cavities in M. tb-infected rabbits. The
example of a cavity wall shows regions identified as collagen.
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Chapter 4
Preliminary studies on the use of
odanacatib to inhibit cathepsin K
during cavity formation in the
rabbit model
Michael E. Urbanowski · Kristina Bigelow · Kevin Bock · Marlene
Orandle · André Kübler · William R. Bishai
“In my own studies on tuberculosis I began
by using the known methods, without
success. But several casual observations
have induced me to forego these methods
and to strike out in a new direction, which
has finally led me to positive results”
by Robert Koch.
translated from German
Die Ätiologie der Tuberkulose (1882)
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4.1 Introduction
The collagenase MMPs and cathepsin K are the two lead candidates for molecular
mediators of tissue matrix destruction in tuberculosis identified by Kübler et al91,131.
In the previous chapter we tested whether inhibition of the collagenase MMPs was
able to reduce tissue destruction and prevent cavitation. Our findings showed that
MMP inhibition did not reduce the occurrence or extent of cavitation in our model
system and suggest that MMP may not be a key mediator in the tissue destruction
phenotype that enables cavitation in tuberculosis. Therefore, in this chapter, we turn
our attention to the second lead candidate mediator, cathepsin K.
Here we provide a series of preliminary experiments aimed to further under-
stand the role of cathepsin K in tuberculosis lung destruction. During our investiga-
tions, we also obtained a small molecule inhibitor of cathepsin K, odanacatib, through
a drug grant from Merck. We conducted a single oral bolus dosing study and show
the pharmacokinetic profile of odanacatib in rabbit plasma. We next used these data
to drive a repetitive dosing predictive model to identify steady-state plasma concen-
tration. This model provides the basis for a proposed rabbit study using odanacatib
to inhibit cathepsin K in vivo. In the final section of this chapter we propose a
study designed to address whether cathepsin K is the critical mediator of lung matrix
destruction in tuberculosis.
4.1.1 The biology of cathepsin K
Cathepsin K is a member of a group of human cathepsins180. The term “cathep-
sin” is derived from the greek word “kathepsein” meaning “to digest,” but does not
imply homology among the cathepsin proteases181. The term was derived from ini-
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tial studies that identified the cathepsins as enzymatic mediators of protein digestion
in lysosomes. Indeed, the cathepsin family is divided by differences in the cleaved
residue on target proteins. Cathepsins B, C, F, H, K, L, O, S, V, W, and X are
cysteine proteases. Cathepsins A and G are serine proteases. Finally, Cathepsins D
and E are aspartic proteases. The cysteine cathepsin sub-group are a homologous
group of proteins and are further divided as endopeptidases (cathepsins F, K, L, S
and V), carboxypeptidases (cathepsin X)180,182, dipeptidyle peptidase (cathepsin C),
aminopeptidases (cathepsin H), or peptidyl dipeptidases (cathepsin X). Formally, the
cysteine cathepsins are classified as the papain-like C1 family proteins of the CA
superfamily of proteases181.
Most of the cysteine cathepsins are expressed in all cells of the human body,
but the expression of cysteine cathepsins K, S, V and W is restricted based on phys-
iological context. Cathepsin K is predominately expressed by osteoclasts and syn-
ovial fibroblasts, but also to a lesser degree in hematopoietic epithelial and fibroblast
cells180,183–185. The gene for cathepsin K is CTSK and is located on a central region
of chromosome 1. At the cell level the cysteine cathepsins are found in both the lyso-
somes and in the extacellular compartment as secreted proteins. These localizations
are consistent with two roles for the cysteine cathepsins. First, they act as digestive
proteins in lysosomes. Second, they have physiological roles as extracellular proteases.
Cathepsin K was originally noticed for its robust ability to cleave bovine skin
collagen during in vitro assays98,186,187. Compared with the other cysteine cathepsins,
cathepsin K has the strongest proteolytic activity against collagen94. Congruent with
these observations, cathepsin K is the only cysteine cathepsin able to cleave both
non-helical and triple-helical collagen conformations under the physiological condi-
tions of the extracellular environment188–190. Therefore, the contemporary perspec-
tive on cathepsin K is as the primary protein mediators of bone-matrix breakdown
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by osteoclasts191.
Although the physiological role of cathepsin K was established in the 1990s,
a corresponding biochemical model was not formalized until the late 2000s. Part
of the reason for the delay was a set of seemingly paradoxical biochemical observa-
tions. First, cathepsin K showed biochemical activity in the range pH 7.0 — pH
5.098,188,189,192 with optimal activity at lysosomal pH, but significantly lower activ-
ity closer to pH 7.0 at the pH of the extracellular environment193. This observation
was consistent with the lysosomal role of cathepsin K but did not explain the strong
collagenase activity observed outside the cell. The second observation was based
on the amino acid sequence of cathepsin K. Investigators noticed that cathepsin K
and closely related cathepsin L contained an allosteric globular region enriched with
positively-charged amino-acids192,194. This spatially ordered positively-charged region
was distinct from other cysteine cathepsins. Finally, studies on cathepsin L revealed
that the allosteric positively-charged surface of cathepsin L-like proteins was optimal
for binding to negatively-charged glycosaminoglycans (GAGs) and that the binding
of GAGs to cathepsin L caused the optimal proteolytic activity to shift towards pH
7.094,195,196. These findings were later confirmed for cathepsin K192,194,197,198.
The current biochemical model for cathepsin K activity is based on compartment-
specific control mediated by pH and GAG binding to cathepsin K. Cathepsin K is
translated in the endoplasmic reticulum and trafficked through the Golgi appara-
tus as a proenzyme with a pro-peptide occluding the active site. This mechanism
of pro-enzyme inhibition is conserved among the cysteine cathepsins95,199. The cys-
teine cathespins are then trafficked as proenzymes from the Golgi to the acidic lyso-
some. The acidic lysosome confers a higher degree of molecular movement on the
cysteine cathespsins and this higher degree of molecular movement mediates acti-
vation. Among the milieu of cysteine cathepsins in the lysosome is cathepsin B.
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Pro-cathepsin B in the acidic environment has enough molecular instability to switch
between a closed (inactive) and an open (slightly active) protease form200,201. The
slightly active protease form is enough to cleave the pro-peptide from of a nearby
cysteine cathepsin, leading to chain-reaction auto-activation in the lysosome. For
cathepsin K, the proenzyme form is a 37 kDa molecule that is cleaved to an active
27 kDa enzymatically active protein191.
Following secretion and in the extracellular compartment, cathepsin K returns
to a basal level of activity at pH 7.2. The binding of a negatively-charged collagen-
matrix associated sulfated-GAGs chondroitin-4-sulfate, chondroitin-6-sulfate, dermatin
sulfate, or hyaluronan at the allosteric positively-charged surface site increases the sta-
bility of the cathepsin K substrate interaction enough to promote optimal activity
at neutral pH198,202–204. Therefore, environmental specificity is a major regulatory
factor over cathepsin K activity. It is also likely that the GAG-cathepsin K complex
is self-potentiating since the cleavage of collagen matrix releases more GAGs into
the peri-cellular environment205. Additional specificity is conferred by cathepsin K
specific active-site confirmation that enables binding to triple-helical collagen190.
Cathepsin K is also susceptible to proteolytic inactivation. The major pro-
tein inhibitors of the cysteine cathepsins are the cystatins, thyropins and serpins181,
but the major mechanism of extracellular cathepsin K inhibition is auto-proteolytic
degradation192. Therefore, cathepsin K activation is tightly regulated in the extra-
cellular environment by substrate-specific factors while inactivation is controlled by
self-limiting proteolytic degradation by cathepsin K and other endopeptidases in the
extracellular environment.
Cathepsin K is the predominant protein mediator of bone absorption, but it is
also implicated in several diseases. Inactivating or partially inactivating mutations in
cathepsin K lead to pycnodysostosis, a congenital disorder characterized by atypically
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dense and brittle bones206. Increased activity in adults is also thought to be a primary
driver of osteoporosis180.
4.1.2 A role for cathepsin K in tuberculosis.
As mentioned in the introduction, cathepsin K was identified as a candidate biochem-
ical mediator of lung-matrix destruction by an RNA-seq study in rabbits modeling
cavitary tuberculosis91. Several additional lines of evidence suggest a role for cathep-
sin K in lung matrix destruction during tuberculosis.
1. Cathepsin K protects against pathologic pulmonary fibrosis. Bhling
et al. used mice deficient in cathepsin K production (CTSK-/- mice) in a drug-
inducible model of pulmonary fibrosis207. Their investigations showed that the
induced fibrosis in CTSK-/- mice was worse than in CTSK+/+ mice. When
cathepsin K overexpressing mice were used in similar experiments, cathepsin
K overexpressing mice showed less pathologic fibrosis than wild-type mice208.
The investigators concluded that cathepsin K was protective against pathologic
fibrosis.
Tuberculosis is a classic example of granulomatous pneumonia common to pathogenic
pulmonary insults that cannot be readily cleared by the immune system. Gran-
ulomas may persist for months or years within the lungs of those with tuber-
culosis, and often the alveolar architecture within a granuloma is first degraded
and then replaced with fibrotic collagen filaments. Therefore, cathepsin K may
play a pivotal role in degrading the extracellular matrix of the lung during
pathologic insult.
2. Cathepsin K gene transcripts accumulate in the lungs of patients
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with necrotic tuberculosis granulomas. Kim et al, found that cathepsin K
expression was increased in lungs of individuals with tuberculosis granulomas88.
This study shows that cathepsin K is transcriptionally upregulated as part of
the host response to M. tb infection and concentrates within granulomas.
3. Multinucleated giant cells from tuberculosis lungs express cathepsin
K. Park et al., stained granulomatous lesions from tuberculosis patients and
showed that multinucleated giant cells within granulomas express cathepsin K92.
Multinucleated giant cells are thought to occur by the fusion of macrophages
and although they are not pathognomonic for tuberculosis, they are commonly
observed in tuberculosis granulomas. The observation that multinucleated giant
cells express cathepsin K is particularly interesting finding since osteoclasts and
multinucleated giant cells share a common monocytic progenitor cell as part of
their lineages of differentiation209.
4. Cathepsin K plasma protein levels are elevated in patients with tu-
berculosis. Kübler et al., performed ELISAs on sputum-culture confirmed
patients with active tuberculosis and healthy blood-donor control patients and
found that the plasma levels of cathepsin K were significantly higher in individ-
uals with tuberculosis91.
5. Cathepsin K gene expression is regulated downstream of TNFα sig-
naling and other common immunological pathways. The control of
cathepsin K gene expression was characterized in osteoclasts101. These stud-
ies show that cathepsin K is regulated along a RANKL/NFAT signaling axis.
RANKL is part of the TNFα superfamily, and TNFα was also shown to influ-
ence osteoclast development and stimulate cathepsin K production.
The members of the TNFα superfamily of signaling molecules are also common
pro-inflammatory signaling molecules and have been shown to drive granuloma
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development in tuberculosis210.
6. Dannenberg et al., identified cathepsin proteases as likely mediators
of tissue breakdown. Work done by the laboratory of Arthur Dannenberg
and collaborators in the 1970s independently identified lysosomal cathepsins as
potential mediators of tissue destruction in tuberculosis83,84,211.
7. Mineralization and ossification of tuberculous lung lesions is a well-
described outcome during chronic infection. Finally, we highlight that
calcification (sometimes termed ossification) is a well-described development in
persistent tuberculous lung lesions. Although purely associative, it is interesting
to consider that chronic insult and cytokine production may create a metaplastic
osteogenic site in the lungs14,27.
4.1.3 Odanacatib: a potent and selective inhibitor of rabbit
and human cathepsin K
We are interested in cathepsin K with two objectives in mind. First, cathepsin K
may be the critical mediator over lung matrix destruction in tuberculosis. This ob-
jective is part of our ongoing studies aimed at identifying the critical mediators of
lung matrix destruction in tuberculosis. Second, cathepsin K may be a clinical tar-
get for host-directed therapy in tuberculosis. We hypothesize that the inhibition of
cathepsin K will promote lung matrix stabilization during the inflammatory response
in granulomas, thereby preventing cavitation and disease transmission.
To test our hypothesis, we looked for a potent, selective, and bioavailable
inhibitor of cathepsin K. Many cathepsin K inhibitors have been synthesized during
the past 20 years212. Considering that cathepsin K is the focus of our hypothesis, we
are interested in several properties:
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1. selectivity for cathepsin K over the other conserved cathepsins.
2. activity against rabbit cathepsin K.
3. activity again human cathepsin K.
Our literature review revealed odanacatib as a well tolerated, potent, and
selective inhibitor of cathepsin K in human studies213,214. During our search we also
considered several other related molecules including L-87372448215 and its parent
molecule, L-00623549216 as a relatively selective cathepsin K inhibitor. These small
molecules were advantageous because they were relatively selective against human
and murine cathepsin K and had previously been tested as pre-clinical agents in
mammalian models. Therefore, the use of these molecules meant that we could also
employ mouse models as part of our experiments217.
Odanacatib was selected as the highest-priority small-molecule inhibitor of
cathepsin K for our investigations. This selection was based on several considera-
tions. First, the IC50 of odanacatib against human cathepsin K is 0.2 nM. Strikingly,
IC50 of odanacatib against rat and mouse cathepsin K is nearly 500 times higher
212.
Furthermore, the rabbit model is advantageous because rabbit cathepsin K shows high
sequence homology with human cathepsin K (94% in rabbits versus 87% in mouse and
88% in rat)and because Gauthier et al. (2008) showed that the IC50 of odanacatib
for rabbit cathepsin K was similar to that of human cathepsin K (1.0 nM for rabbit
cathepsin K versus 0.2 nM for human cathepsin K)213. Finally, ovariectomized rab-
bits were recently used to model osteoporosis and treated with odanacatib to show
biological effect218,219. Therefore, we reason that the use of odanacatib to inhibit
cathepsin K in the rabbit model of cavitary tuberculosis is an appropriate system for
this study from both a pathologic and biochemical perspective.
Odanacatib was also advantageous because it was shown to be well-tolerated
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during dosing in both mammalian and human studies214,218,220,221. Odanacatib was
developed by the Merck corporation as a treatment for osteoporosis. The drug was
terminated during phase III clinical trials due to an unacceptable risk of stroke222.
During all clinical trials, odanacatib continued to show clinical efficacy in reducing
bone matrix depletion.
4.2 Results
4.2.1 Cathepsin K expression is increased following in vitro
infection of macrophages with M. tb
We began our studies on cathepsin K in tuberculosis pathology by asking whether in-
creased cathepsin K gene expression was a feature of a global transcriptional response
to infection by M. tb. We used unstimulated murine J774 macrophages, a common
laboratory macrophage line, for our in vitro studies. Macrophages were seeded onto
6-well plates at a concentration of 105 cells/mL and exposed to approximately 106
bacilli to cause a multiplicity of exposure of 1:10. The multiplicity of exposure was
carefully chosen following a series of careful titration experiments to yield >90%
macrophage viability after 24 hours. During our experiments, the supernatant was
washed after a four-hour infection period and the infected macrophages were allowed
to incubate for an additional 24 hours. RNA was extracted from all wells of the
experiment and transcript levels were determined by Q-PCR (Fig 4.1).
The results of three biological replicates demonstrate that cathepsin K tran-
scription was greater in macrophages infected with M. tb compared with media-wash
controls (Fig 4.1B). In our panel, cathepsin B and cathepsin C transcription was
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In vitro Cathepsin K gene transcription changes following macrophage
infection by M. tb
Figure 4.1: The influence of in vitro M. tb infection on cathepsin K transcription in macrophages.
(A) Overview of in vitro macrophage infection study design. (B) Relative accumulation of selected
gene transcripts assessed by Q-PCR in infected macrophages. All fold-changes are given relative to
uninfected sham-treated (media exchange) controls.
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also increased, but to a lesser extent than cathepsin K. As a negative control, we
probed the transcriptional changes in SEMA3a, a protein implicated in control over
neuronal growth. The levels of SEMA3a were not changed following M. tb infection.
We used TNFα gene transcription as a positive control and noted that TNFα was
highly upregulated following M. tb infection. Taken together, these results indicate
that cathepsin K transcription is increased in macrophages following in vitro infection
with M. tb.
4.2.2 Immunohistochemistry staining shows that cathepsin
K is enriched in the walls of rabbit cavities.
We next asked whether cathepsin K could be detected in the lungs of rabbits infected
with M. tb and whether the spatial distribution of cathepsin K was focused at the sites
of granulomas and the walls of cavities. We obtained fixed tissue samples from rabbits
modeling tuberculosis cavities and stained these tissue sections using an anti-human
cathepsin K antibody (Fig 4.2).
The pattern of staining revealed that cathepsin K was enriched in the walls of
cavities. Staining was not observed, as expected, in the necrotic zone of the cavity
(Fig 4.2D). As a control, we also stained tissue sections without a primary anti-human
cathepsin K antibody and confirmed that these slides showed no staining consistent
with the signal from vulcan fast red chromogen used during these experiments (data
not shown). These results demonstrate that cathepsin K protein is enriched in the
walls of cavities and provides further evidence that cathepsin K expression is upreg-
ulated in the lungs during the granulomatous response to M. tb infection.
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Anti-cathepsin K immunohistochemisty staining of rabbit cavity walls
Figure 4.2: Anti-cathepsin K immunohistochemisty staining of rabbit cavity walls. (A) H&E
staining of cavity from a rabbit infected with M. tb. Black dashed line indicates the boundary of
granulomatous pneumonia. Green dashed line indicates the boundary of necrosis. Yellow arrows
indicate cavity space. (B) A serial section with A, stained with anti-cathepsin K. The chromogen is
vulcan-fast-red. Scale bars for A and B = 5 mm. (C) Enlarged area from the box drawn in A. (D)
Enlarged area from the box drawn in B. Scale bars from C and D = 200 µm.
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4.2.3 Cathepsin K transcripts accumulate in the cavity walls
of rabbits modeling tuberculosis cavities.
Our previous results indicated that cathepsin K was expressed in the lungs of rabbits
infected with M. tb and that the highest expression levels coincided with granulo-
matous inflammation and in the walls of cavities. Next, we performed a survey of
cathespin K gene expression in a similar method to the survey performed by Kübler
et al91. We modeled cavities using a bronchoscope to deliver a high concentration
of M. tb bacilli directly into the lungs. Kübler previously characterized this model
to show pathologic patterns consistent with tuberculosis cavitation56. Rabbits un-
derwent cavitation one month following bronchoscopic inoculation and we extracted
tissue from the rabbit lungs at varying distances from the walls of cavities. We then
extracted RNA from these samples and performed Q-PCR analysis to assess the rel-
ative enrichment of cathespin K transcripts (Fig 4.3).
We compared tissue from normal-appearing lung regions to tissue close to
cavity walls and tissue from the cavity walls and saw that tissue close to the cavity
wall and from the cavity wall showed increased levels of cathepsin K gene expression.
From these experiments, we concluded that the rabbit response to M. tb infection
included a phenotype with increased cathepsin K expression, similar to the pattern
observed in tuberculosis.
4.2.4 Plasma concentrations of odanacatib in rabbits follow-
ing a single oral bolus dose confirms suitable pharma-
cokinetics for in vivo studies.
We wrote and received a drug grant from Merck to investigate the effects of odanacatib-
mediated cathepsin K inhibition on tuberculosis cavitation. From this grant, we
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Relative abundance of cathepsin K transcripts in the walls of rabbit
cavities
Figure 4.3: Relative abundance of cathepsin K transcripts in the walls of rabbit cavities compared
to areas not involved with disease. Relative abundance of transcripts was assessed by Q-PCR.
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received 150 grams of odanacatib for our study. We began our investigations by
performing a single oral bolus dose pharmacokinetic study. During this study, we
administered 5 mg/kg odanacatib per os in corn oil to three rabbits. This dose was
similar to the dose of odanacatib used during human studies and was shown to be safe,
tolerable, and efficacious214. We collected plasma from rabbits at various time-points
following dosing according to our study plan. The plasma samples were analyzed us-
ing a liquid-chromatography mass-spectrometry protocol optimized for the detection
of odanacatib (Fig 4.4).
The results of our initial PK study showed that 5 mg/kg oral dosing achieved
a Cmax of 284 nanomolar and this was consistent with previously published results
following scaled dosing in humans214 (Table 4.1). However, our study reported a
significantly longer period between dosing and Cmax with a Tmax of 72 hours compared
with 10 hours reported by Stoch et al214. We hypothesize that this difference may
be due to the use of corn oil which is known to delay uptake of drugs in rabbits.
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Concentrations of odanacatib in plasma following a single oral dose
Figure 4.4: Concentrations of odanacatib over time in rabbit plasma following a single oral bolus
dose of 5 mg/kg by body weight. Plasma concentrations of odanacatib were assessed by LC-MS. (A)
Individual concentration curves for each of the three rabbits involved in the study. (B) Consensus




































































































































































































4.2.5 A pharmacokinetic model for repetitive dosing predicts
a dosing pattern of 10 mg/kg daily achieves steady-
state concentrations between 300 and 600 nanomolar.
We next sought to design and implement a study where odanacatib was used to
inhibit cathepsin K. One critical parameter for this study-design is the dosing strategy.
From previous reports, we identified 300 — 600 nanomolar as a steady-state plasma
concentration range that will achieve pharmacologic inhibition of cathepsin K.
We implemented our steady-state model using the parameters derived from
our pharmacokinetic study (Fig 4.5). These parameters were:
1. Cmax: The maximum concentration achieved during single oral bolus dosing.
2. Tmax: The time until the maximum concentration.
3. T1/2: The half-life of the drug in the plasma.
4. Tlag: The time between dosing and the initial increase in plasma concentration.
The simulation suggested that a dosing strategy of either 2 mg/kg every 24
hours or 4 mg/kg every 48 hours would achieve steady-state concentrations between
300 — 600 nanomolar (Fig 4.5A). However, we noticed that although most of the
parameters used to drive our steady-state model agreed with previously published
reports, our described Tmax was considerably longer than the 10 hours reported pre-
viously214. Therefore, we implemented our steady-state model again, but this time
substituting our estimate for Tmax with the previously reported Tmax of 10 hours (Fig
4.5B). The output from our revised simulation suggested that a dosing strategy of
either 10 mg/kg every 24 hours or a dosing strategy of 20 mg/kg every 48 hours would
maintain steady-state concentrations between 300 — 600 nanomolar. We selected 10
108
mg/kg every 24 hours as a conservative strategy to build a study-design for inhibition
of cathepsin K during cavity formation in rabbits.
4.2.6 A proposed study-design to investigate the effects of
cathepsin K inhibition during cavity formation in rab-
bits.
Study overview: Rabbits will be infected by five low-dose aerosol exposures to
tuberculosis. From our previous work, we expect that cavitation will occur at a high
frequency (60-80% of animals) between study weeks 8 – 10. We identified a treatment
period beginning at study-week 2 and continuing through study-week 10. During this
time we expect pre-cavity lesions to undergo a necrotic transition, the commitment
step toward cavitation.
Fifteen rabbits will be randomized to a treatment group receiving odanacatib
and 10 rabbits will be randomized to a control group to receive vehicle. Our previous
work with this model suggests that these numbers will sufficiently power the study
to discern a true change in the frequency of cavitation (see methods appendix A
for details of power calculation). Rabbits in the treatment group will receive 40
mg/kg/day per os between weeks five and ten. The study will last a total of 14 weeks
(Fig 4.6).
Study outcomes and evaluation: Data collected from this study will be in
three different modalities: (1) computer tomography (CT) scans, (2) gross pathology
quantification, and (3) histology and immunohistochemistry.
1. CT scans: Our biosafety-level 3 animal facility allows us to collected CT scans
of infected rabbits. To monitor cavitation during the study we will collect
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Predicted steady-state plasma concentrations of odanacatib
Figure 4.5: Predicted steady-state plasma concentrations of odanacatib during repetitive dosing.
(A)Predicted plasma concentrations of odanacatib over time when all parameters for the steady-
state predictive algorithm are based on the single oral bolus dosing study. (B) Predictive plasma
concentrations of odanacatib over time when the Tmax is set to 10 hours based on previous reports.
All other parameters are the same as in A.
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high-resolution CT scans of rabbits once every two weeks. These data will be
quantified to give disease metrics at intermediate study time-points including
number of cavities per animal and the average size of cavities between groups.
2. Gross pathology quantification: Following the study end-point the rabbits
will be sacrificed. Lung, spleen, lymph nodes, liver, and bone-samples will be
collected and fixed. Fixed lung will be dissected and photographed. These
photographs will be used to quantify the extent of disease in lungs and validate
radiological findings.
3. Histology and immunohistochemistry: Once the fixed organs are dissected
and photographed, we will systematically collect histology samples. Samples
will be paraffin embedded, section, and stained with H&E, Masson’s trichrome
stain and an anti-cathepsin K antibody that we previously optimized for rabbit
samples. Using the Masson’s trichrome stain, we expect to quantify the extent of
collagen remaining in infected foci and the extent of collagen deposition around
fibro-necrotic lesions.
Ethical considerations and safe animal practices: All animals will be
housed in the Animal Biosafety-level 3 facility at the Johns Hopkins University School
of Medicine. Researchers working with infected animals adhere to strict facility guide-
lines regarding appropriate personal protective equipment. All animals in the study
will be monitored daily for fecal/urine output, appearance and weight. Animals that
show signs of distress or disease will be evaluated by a member of the Johns Hop-
kins veterinary team. All procedures described in this proposed study are acceptable
under an active IRB protocol in the Bishai Laboratory as approved by the Johns
Hopkins University Animal Care and Use Committee.
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4.3 Discussion
Our studies further support that cathepsin K expression is increased in the lungs
of tuberculosis patients. These studies agree with past work by Kim et al. who
showed that cathespin K transcription was increased in the caseous pneumonia of
tuberculosis cavities and by Park et al., who observed that multinucleated giant cells
in tuberculosis lesions express cathepsin K by immunohistochemistry staining88,92.
Our work is a continuation of Kübler et al.’s studies demonstrating that increased
cathepsin K expression is also a feature of the host-response to M. tb infection in
rabbits91.
In the studies described above we demonstrate that macrophages infected by
M. tb show increased transcription of cathepsin K by Q-PCR. This experiment shows
that macrophages in mono-cell culture can express cathepsin K when infected by M.
tb, thereby providing plausible in vitro evidence that macrophages and multinucleated
giant cells can be the agents of cathepsin K expression in granulomatous pneumonia.
Our in vitro experiments are not able to determine whether the observed increase in
cathepsin K transcription is a biologically relevant process and so it is possible that
cellular members of the granuloma (ie. fibroblasts, neutrophils, or lymphocytes) also
participate in cathepsin K expression. It is also possible that a biologically relevant
increase in cathepsin K expression within granulomas is driven by cytokine cross-talk
between different cell-types.
We also show that the walls of rabbit cavities are enriched in cathepsin K by
immunohistochemical staining. Again, this survey has several limitations. First, a
review of the stained tissue section shows little variability in vulcan fast red chromogen
hue between cell-types of the cavity wall. We propose two possibilities.
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1. Many cells of the cavity wall are influenced by cytokines to increase cathespin
K expression in granulocytic pneumonia.
2. Staining was not specific for cathespin K.
Two lines of evidence argue against non-specific staining.
1. We noticed that the necrotic debris at the interior edge of the cavity did not stain
brightly for cathepsin K and this supports specificity for the primary antibody.
We expect the necrotic debris of the cavity edge to be enriched in “protein-spill”
from dying cells, and so would likely stain brightest if non-specific staining was
a major contributor to the Vulcan-fast-red signal.
2. Our control slides, stained only with secondary-antibody, were devoid of vulcan-
fast-red hue.
The second important limitation of our immunohistochemistry survey relates
to the biology of Cathepsin K. Our primary anti-cathepsin K antibody is not specific
for active cathepsin K and likely recognizes the 37 kDa inactive form with similar
affinity to the 27 kDa active form. Therefore, the immunohistochemistry assay results
presented above should not be interpreted as areas of increased cathepsin K activity.
We used Q-PCR to survey regions of rabbit lung of varying proximity to
cavities induced by M. tb infection. Our results show a proximity-dependent increase
in the transcription of cathepsin K. Tissue areas closer to the walls of cavities showed
an increased concentration of cathepsin K transcripts. These studies further support
granulomas and cavity-walls as the epicenters of cathespin K production. These
results also validate the rabbit model as an appropriate system to further study the
role of cathepsin K in the development of tuberculosis cavities.
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In our final set of investigations, we obtained 150g of odanacatib and con-
ducted a preliminary pharmacokinetic study in rabbits by measuring the plasma
concentration of odanacatib following single oral bolus dosing. The results of our
pharmacokinetic study show that odanacatib has good properties for an in vivo study
to investigate the effects of cathespin K inhibition during cavity formation. Our pro-
posed study design is also described.
We hypothesize that the inhibition of cathepsin K will stabilize the extracel-
lular matrix of lung tissue, thereby preventing cavitation following repetitive aerosol
challenge. In our study design we defined sensitive metrics for cavity formation and
progression that will allow us to assess the effects of cathespin K inhibition. However,
in careful consideration of our hypothesis, we also propose several potential pitfalls
during our study.
1. Inhibition of cathepsin K may damage the immune response. If mono-
cytes use cathepsin K as a way to move through lung tissue, the inhibition of
cathepsin K may prevent monocyte migration to the foci of lung infection.
2. The disruption of collagen breakdown may cause increased fibrosis.
Bhling et al. and Srivastava et al., concluded that cathespin K was protective
against pathologic lung fibrosis. It is possible that inhibition of cathepsin K in
the context of M. tb infection will cause wide-spread pathologic fibrosis207,208.
3. It may be impossible to uncouple matrix breakdown from necrosis at
the border between the cellular and necrotic regions of the cavity wall.
Finally, it is possible that matrix breakdown is an unavoidable consequence
of widespread necrosis and that cell death releases a proteolytic cascade of
lysosomal enzymes. If this is the case, then multiple proteolytic enzymes from
many families might participate in matrix breakdown, therefore single-agent
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small-molecule therapy is unlikely to change the rate of cavitation.
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Proposed study design.
Figure 4.6: Proposed study design to investigate the effects of odanacatib-mediated inhibition of
cathepsin K during cavity formation in rabbits.
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192. Novinec, M., Kovačič, L., Lenarčič, B. & Baici, A. Conformational flexibility
and allosteric regulation of cathepsin K. Biochemical Journal 429, 379–389.
issn: 0264-6021, 1470-8728 (July 15, 2010).
193. Jordans, S. et al. Monitoring compartment-specific substrate cleavage by cathep-
sins B, K, L, and S at physiological pH and redox conditions. BMC Biochemistry
10, 23. issn: 1471-2091 (Sept. 22, 2009).
194. Li, Z., Kienetz, M., Cherney, M. M., James, M. N. G. & Brömme, D. The
crystal and molecular structures of a cathepsin K:chondroitin sulfate complex.
J. Mol. Biol. 383, 78–91. issn: 1089-8638 (Oct. 31, 2008).
195. Dubin, G. Proteinaceous cysteine protease inhibitors. CMLS, Cell. Mol. Life
Sci. 62, 653. issn: 1420-682X, 1420-9071 (Mar. 1, 2005).
196. Mason, R. W. & Massey, S. D. Surface activation of pro-cathepsin L. Biochem-
ical and Biophysical Research Communications 189, 1659–1666. issn: 0006-
291X (Dec. 30, 1992).
197. Almeida, P. C. et al. Cysteine Proteinase Activity Regulation A POSSIBLE
ROLE OF HEPARIN AND HEPARIN-LIKE GLYCOSAMINOGLYCANS. J.
Biol. Chem. 274, 30433–30438. issn: 0021-9258, 1083-351X (Oct. 22, 1999).
198. Li, Z., Hou, W.-S. & Brömme, D. Collagenolytic Activity of Cathepsin K Is
Specifically Modulated by Cartilage-Resident Chondroitin Sulfates. Biochem-
istry 39, 529–536. issn: 0006-2960 (Jan. 1, 2000).
199. Sivaraman, J., Lalumière, M., Ménard, R. & Cygler, M. Crystal structure of
wild-type human procathepsin K. Protein Sci 8, 283–290. issn: 0961-8368 (Feb.
1999).
200. Rozman, J., Stojan, J., Kuhelj, R., Turk, V. & Turk, B. Autocatalytic process-
ing of recombinant human procathepsin B is a bimolecular process11Dedicated
to Prof. Pavao Mildner on the occasion of his 80th birthday. FEBS Letters 459,
358–362. issn: 0014-5793 (Oct. 15, 1999).
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A.1 Commitment to animal welfare and ethics state-
ment
All animals will be housed in the Animal Biosafety-level 3 facility at the Johns Hopkins
University School of Medicine. Researchers working with infected animals adhere to
strict facility guidelines regarding appropriate personal protective equipment. All
animals in the study will be monitored daily for fecal/urine output, appearance and
weight. Animals that show signs of distress or disease will be evaluated by a member
of the Johns Hopkins veterinary team.
All procedures described in this document are acceptable under an active IRB
protocol in the Bishai Laboratory as approved by the Johns Hopkins University Ani-
mal Care and Use Committee: Protocol Number: RB14M418. Oversight and accredi-
tation of the Johns Hopkins Animal Care and Use Committee and facilities is provided
by the Association for the Assessment and Accreditation of Laboratory Animal Use
(AAALAC) International.
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A.2 Repetitive aerosol infection of rabbits
Female New Zealand White rabbits (2.5 — 3.5 kg) were purchased from Robinson
Services (Mocksville, NC) and housed individually in a BSL-3 facility without cross-
ventilation. Rabbits were infected in a Madison aerosol droplet generation chamber
(College of Engineering Shops, University of Wisconsin, Madison, WI). The aerosol
inoculum for the chamber was prepared by dilution of log-phase bacterial culture of
M. tb H37Rv to the appropriate OD600 for each experimental group.
A.3 Clinical care plan for study rabbits
A.3.1 Criteria for euthanasia
Weight Loss: Progressive 5-8% per week sustained over 3 weeks despite fluid
administration and dietary supplementation.
Respiratory distress or dyspnea: (1) any indication of hunched posture
and/or nostril flaring. (2) bluish visible mucosa, (2) loss of appetite, (3) CNS
depression, (4) lack of grooming, (5) soiled fur are criteria for immediate eu-
thanasia.
Low fecal/urine output: Sustained low fecal/urine output over 3 weeks de-
spite fluid administration and dietary supplementation.
Poor appetite: Sustained poor appetite over 3 weeks despite fluid adminis-
tration and dietary supplementation.
A.3.2 Intervention plan in cases of weight loss and/or low
fecal/urine output
Fluid administration: Rabbits will receive 100-150 mL of lacate ringers per
day. Urine output will be monitored.
Dietary supplementation: Rabbits will receive dietary supplements such
as fresh/dried fruits and vegetables, additional alfalfa hay, enrichment treats
and/or critical care recovery food.
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Veterinary Consultation: An animal-resources veterinarian will be con-
sulted.
Increased and progressive monitoring: Animals covered under the inter-
vention plan will receive increased monitoring and their status will be recorded
daily
Unchanged or progressive worsening: Animals that continue to decline
in fecal/urine/appetite and/or dehydration metrics will trigger criteria for eu-
thanasia (above).
A.3.3 Protocol for procedure-level rabbit anesthesia
Animals are weighed and clinical observations are recorded. Injectible anesthetics are
dosed by body weight.
1. Ketamine: 17-35 mg/kg IM
2. Acepromazine: 0.1-0.25 mg/kg IM
3. Xylazine: 5-10 mg/kg IM
Maintenance of anesthesia was mediated by 1-2% isofluorane in an air/oxygen
mixture.
A.3.4 Protocol for rabbit euthanasia
Rabbits undergo anesthesia under the standard protocol (above). The rabbit is in-
jected with pentobarbital solution (Euthasol) administered IV at 100 mg/kg body
weight. Pupil reactivity and absence of heart-beat by palpation will be used to con-
firm death.
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A.4 Rabbit intubation and breath-holding for CT
scans
Intubation is used to achieve a lung-field immobilizing breath-hold conditions during
CT imaging. Rabbits undergo standard anesthesia (above) and are maintained on 1-
2% isofluorane in an oxygen/air mixture. A cuffed pediatric endotracheal (ET) tube
is placed under endoscopic guidance. Rabbits are placed into the CT scanner and the
ET tube is connected to a pressure-regulator. Rabbits undergo breath-holding for a
period of 12-seconds. This protocol is shown to be safe for rabbits and is approved
as part of the Bishai Lab standard Animal Care and Use Committee protocol.
Intubation was also used for bronchoscopic instillation of M. tb suspension
inoculation into the lungs. In this case, a non-cuffed pediatric ET tube was used to
guide the bronchoscope probe to the site of infection. The non-cuffed pediatric ET
tube is necessary to allow movement of air around the ET tube while the bronchoscope
probe is in the lungs.
A.5 Cipemastat dosing
Cipemastat was obtained from the Roche Corporation (Basel, Switzerland) and the
identity of the compound was confirmed by LC/MS.
Rabbits in the treatment group were given 100 mg/kg cipemastat orally by
body weight adjusted weekly using PediaSure as a vehicle. The concentration of
cipemastat in the vehicle was 100 mg/mL. Cipemastat treatment and vehicle shams
were administered daily between study weeks 5 and 10.
A.6 Pharmacokinetic analysis of cipemastat in plasma
Three rabbits were given a single 100 mg/kg oral dose of cipemastat. Peripheral
blood samples were collected every 30 minutes, then at 4, 6, 8, 12, and 24 hours.
Experimental samples were analyzed in tandem with a standard curve pre-
pared in untreated rabbit plasma. Plasma concentrations of cipemastat were detected
and quantified by liquid chromatography- tandem mass spectrometry (LC-MS/MS;
AB SCIEX QTRAP 5500). Liquid chromatography was carried out by reverse phase
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gradient elution between 90% mobile phase A (0.1% formic acid in water) to 95%
mobile phase B (100% acetonitrile) over 2 minutes on a ZORBAX Eclipse Plus C18
column (2.1 x 50 mm, 3.5 µm, Agilent Technologies, Part No. 9597432-902). Selected
ion monitoring of the cipemastat parent ion at m/z 437.2 identified daughter ions at
m/z 262.2 and 404.3. These transitions were supported by predicted masses in a
cipemastat fragmentation map and agree with transitions identified by Hopfgartner
et al. (2003)223.
Cipemastat concentration in eluate was measured as area under the curve for
mass transition peaks. Analysis was conducted using Analyst (SCIEX) and com-
panion software MultiQuant (SCIEX). Pharmacokinetics analysis (PK) of total drug
exposure over time (AUC0-24), half-life (T1/2 ), concentration maximum (Cmax) and
time of concentration maximum (Tmax) were calculated using 2 compartment 1st order
pharmacokinetics analysis with WinNonlin software (version 7.0, Pharsight Corp).
A.7 Computerized tomography scans
Rabbits were imaged using a CereTom 8-slice clinical computerized tomography (CT)
scanner with a 32.5 cm bore diameter (NeuroLogica, Boston, MA). To achieve recon-
structions in the absence of motion artifact, rabbits underwent breath-holding during
CT scans as described by Kübler56.
A.8 Identification of cavities from CT reconstruc-
tions
CT reconstructions were viewed using VivoQuant software (Invicro). Lung cavities
were radiologically identified from CT scan reconstructions as a contiguous set of
volume elements (voxels) whose size is defined by the limit-of-resolution of the CT
scanner, within the lungs, with densities close to air (-1000 – 910 Hounsfield unit
[HU]) and encapsulated by consolidation defined as a continuous region of voxels
with densities similar to water (-725 – 1000 HU). This radiological definition was
consistent with the consensus definition for cavities advanced by Gadkowski and Stout
(2008)2. Contiguous airspace and consolidation regions were selected by connected
thresholding in the density range for each landmark. Continuity of consolidation
around the airspace was confirmed by eye.
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A.9 Lung extraction and fixation
After 14 weeks, rabbits were sedated and euthanized. Lungs were removed and pho-
tographed and then gently infused with intratracheal 10% neutral buffered formalin
and fixed for 48 hours.
A.10 Quantification of the extent of lung disease
Gross images were obtained using a Nikon D3200 digital camera and a Nikon NIKKOR
lens and analyzed with ImageJ to identify the areas of visually diseased lung as a frac-
tion of the total area of splayed lung224. This fraction was used as an estimate of the
percentage of diseased lung.
A.11 Histology and trichrome quantification
Transverse lung slices were collected for paraffin embedding and histologic section-
ing. Serial 5 µm sections were stained using hematoxylin and eosin (H&E), Masson’s
trichrome stain, or the acid-fast stain. Image capture for semi-quantitative trichrome
quantification was performed on a Nikon Eclipse 90i microscope with attached Nikon
DS-Ri1 color camera, and analyzed using NIS Elements Advanced Research soft-
ware (Nikon Instruments, Melville, NY). Regions of interest (ROIs) included the full
thickenss of the cavity wall while excluding necrotic debris and air space at the cavity
interior. Positive staining was calculated as a percentage of the total ROI.
A.12 Collagen cleavage assay by MMP-1
Recombinant human MMP-1 (BioVision, Milpitas CA) was added to a solution of
type I collagen (Thermo Fisher Scientific, Waltham MA) in PBS at a molar ratio
of 1:5. 100 µL Novex Zymogram 1X Developing Buffer (Thermo Fisher Scientific,
Waltham MA) with or without 1µg cipemestat was added to this solution prior to
incubation at 37◦ C for 24 hours. At 24 hours, an equal volume of EDTA was added
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to stop the cleavage reaction, and the products were briefly boiled and subjected to
SDS-PAGE on a Mini-Protean TGX precast gel (Bio-Rad, Hercules CA).
A.13 Rabbit infection by bronchoscope guided in-
stillation
Rabbits were anesthetized by the standard protocol (described above. A 2.0-mm flex-
ible Pentax FB-8V pediatric broncoscope (Pentax, Montvale, New Jersey) was guided
into 1 lower lobe. A length of 90 cm long TE-40 plastic tubing was advanced down
the bronchoscope probe and into the distal branches of the bronchial tree until slight
mechanical resistance was felt by the operator. 400 µL of 1.0 · 104 CFU/mL bacilli
in PBS was instilled through the flexible tubing and into the lung. The deadspace of
the 90cm of flexible tubing is 200 µL.
A.14 Histologic and immunohistochemical stain-
ing of rabbit samples
Tissue was resected, formalin fixed in 10% NBF and paraffin embedded. Tissue
sections were cut into 4 µm sections. Serial sections were stained for both hematoxylin
and eosine or remained unstained for immunohistochemistry.
For CTSK immunohistochemical analysis, sections were washed in xylene,
rehydrated and heated by microwave for 20 minutes in unmaking solution (Vector
Laboratories, Burlingame, California; reference H-3300). Tissues were incubated for
30 minutes in serum-free protein blocking agent (Dako, Carpinteria, California; ref-
erence X0909) and incubated with monoclonal mouse anti-human CTSK primary
antibody (AbD Serotec, Oxford, United Kingdom; reference MCA5232Z; 60 minutes)
and then with biotinylated goat anti-mouse Fc secondary antibody (30 minutes). The
complex was coupled to alkaline phosphatase by biotin and avidin (Vector Labora-
tories, Burlingame, California; reference AK-5000). The development step used the
Vulcan Fast Red chromagen (Biocare, Concord, California; reference FR805) and
hematoxylin counterstain. To control for nonspecific signal from secondary antibody
binding or chromogen development, we stained serial tissue sections in the absence of
primary antibody.
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A.15 Repetitive dose modeling for steady-state plasma
concentration in rabbits
Pheonix modeling software was used to model various doses of odanacatib as steady-
state concentration between 300 nM and 600 nM. Pharmacokinetic data was used to
fit slopes for absorption and elimination kinetics.
A.16 Power calculations for rabbit studies
Power calculations for our rabbit studies are based on previous work in the rabbit
model. A group of 12 rabbits was exposed to mycobacterial antigen before experi-
mental infection and was compared with a group of rabbits that was not exposed to
mycobacterial antigen before infection. The pre-infection antigenic challenge provides
an experimental intervention known to produce a significant reduction in disease at
12-weeks in both guinea-pigs and rabbits.
Parameters for Power Calculations:
 Mean Fraction of Lung as Disease in Antigen-experience group: 0.05
 Mean Fraction of Lung as Disease in Antigen-näıve group: 0.15
 Standard Deviation (Average for both groups): 0.10
 Sampling Ratio (antigen experience/antigen-nave): Varies by experi-
mental plan. For example, for the proposed odanacatib rabbit experiment this
parameter is 1.33 (20/15, from experimental plan).
 Power (1-β): 0.90
 Type I error rate, α: 5%
 Sample Size of the Antigen-nave group: Varies by experimental plan. For
example, for the proposed odanacatib rabbit experiment, this parameter is 15
rabbits.
 Decide between one or two-sided sample test comparing the means
of two groups for a difference: Varies by hypothesis and experimental plan.
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Appendix B
Innovations to reduce the pain
and/or distress consistent with the
3Rs of animal welfare
B.1 Refinement: ET-tube placement by endoscopic
guidance
The standard method of ET tube placement in rabbits is challenging because of the
elongated oropharynx which precludes visual confirmation of the ET tube in the
trachea and not the esophagus. The current standard of practice is blind placement
of the ET tube. To refine this technique, we innovated the use of a bronchoscope
running along the ET tube to visually confirm placement of the ET tube in the
trachea. Using this new technique, we have shown a significant decrease in the time
needed to place the ET tube and incidental jostling and trauma to the laryngeal
anatomy during placement.
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B.2 Reduction: Multi-parametric disease outcomes
reduce number of study rabbits
Pathology data in rabbits is collected using three different modalities: (1) Progressive
CT scans, (2) Gross Pathology, (3) Histology and immunohistochemistry. The use
of these three sensitive metrics of disease severity and healing allows us to reduce
the number of animals needed to test our hypothesis. CT scanning in-particular
allows temporal following of disease and allows the research team to resolve trends in
disease that might otherwise require intermediate animal-sacrifice time-points, greatly
increasing the number of animals in these studies.
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